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ABSTRACT OF DISSERTATION

EFFICACY OF PREBIOTIC DIETARY INTERVENTION TO MITIGATE RISKS
FOR DEMENTIA VIA THE GUT-BRAIN AXIS
Alzheimer’s disease (AD) is the most common form of dementia with
various risk factors including age, environmental factors such as brain injury and
genetic factors, such as the E4 allele of the Apolipoprotein gene. Presence of the
APOE4 allele increases AD risk by two- to four- fold. Recent studies have shown
that mild traumatic brain injury (mTBI), even without loss of consciousness,
increases risk of dementia diagnosis by more than two-fold in military personnel
and is also a significant environmental risk factor for developing dementia in the
general population. The gut-brain axis (GBA) or bi-directional communication
between the brain and gut microbiome, has been a topic of investigation in
mitigating symptoms after mTBI and throughout AD development. The gut
microbiome can be modulated to improve one’s overall health. One way to
manipulate the composition of the gut microbiome is by the ingestion of
prebiotics, non-digestible carbohydrates that promote the growth of beneficial
bacteria. The prebiotic that will be employed in these studies is inulin, which is
found in chicory root and other vegetables, such as broccoli. The literature
suggests that manipulation of the gut microbiome may be actionable to reduce
symptoms after mTBI and decrease risk for dementia. We will test the hypothesis
that modulating the gut microbiome with prebiotic inulin will reduce symptoms of
mTBI and will decrease risk of AD-like symptoms in animal models.
KEYWORDS: Dementia, Alzheimer’s Disease, mild traumatic brain injury, gut
brain axis, prebiotic inulin, magnetic resonance imaging
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CHAPTER 1. BACKGROUND
1.1

Risk Factors for Alzheimer’s Disease and Other Dementias
Alzheimer’s disease (AD) is the most common form of dementia

with various risk factors including age, environmental factors and genetics [1].
AD is split into different subtypes based on age and genetic predisposition [2].
AD beginning after the age of 65 is known as sporadic, or late onset AD, and
makes up 95% of cases [2]. For the purposes of this dissertation, references to
Alzheimer’s disease will be to sporadic AD. The E4 allele of the Apolipoprotein
(APOE) gene confers the greatest genetic risk for developing sporadic AD,
increasing risk by two- to four- fold [1]. Additionally, recent studies have shown
that mild traumatic brain injury (mTBI), even without loss of consciousness,
increases risk of dementia diagnosis by more than two-fold in military personnel
[3] and is also a significant environmental risk factor for developing dementia in
the general population [4]. The next sections will outline the genetic (APOE4)
and environmental (mTBI) risk factors for dementia and AD studied in this
dissertation.

1.2

APOE Overview
Protein aggregations such as amyloid beta plaques and tau tangles

are common hallmarks of AD. However, there are also many risk factors for the
development of AD, the chief of which is increased age [1]. Genetic risk factors
that contribute as well, with the E4 allele of the APOE gene conferring the
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greatest risk [5]. Individuals carrying the APOE4 allele are two- to four- fold
more likely to develop AD compared to non-carriers [6]. APOE is a class of
lipoprotein transport proteins that is mainly produced and secreted in the liver but
is also produced in other organs, including the brain [7]. APOE is involved in
catabolism of lipoproteins, and has a strong affinity for lipids and phospholipids,
with a direct impact on metabolism [7].

The apolipoprotein E gene has three isoforms in humans which
play various roles in the development of AD. APOE2 is protective against AD,
APOE3 is neutral towards the disease and APOE4 increases the risk of
developing AD [8] . Apolipoprotein E allele frequency in the human population
varies considerably. APOE3 is the most common, with 77% of the population
carrying this allele. APOE4 is carried by around 15% of the population and
APOE2 is seen in just 8% [9].

Intriguingly, APOE2 and APOE4 only vary from APOE3 by one
amino acid of the 299 that make up the protein: APOE2 has a cysteine at 112
and 158, APOE3 contains a cysteine at 112 and an arginine at 158 and APOE4
contains an arginine at both 112 and 158 [8]. The conformational change that
results from this single amino acid substitution has a profound effect on one’s
risk for the development of AD and recovery from cerebral trauma [7]

2

1.2.1 Role in Alzheimer’s Disease and Dementia
APOE4 plays various roles in the development of AD. One of the
hallmarks of AD is the accumulation of amyloid beta plaques [10]. As mentioned
above, APOE3 and APOE4 only vary by one amino acid, but APOE4 increases
one’s risk of AD development whereas APOE3 does not. It is thought that
APOE4 may contribute to increased AD risk because of a higher affinity for
amyloid-beta based on its lipid-binding domain [11]. Due to this higher affinity,
APOE4 decreases amyloid beta clearance, causing increased amyloid beta
plaque deposition in the brain, and, ergo, risk of AD [11].

Accumulating evidence points to systemic metabolic dysfunction
playing a role in AD risk as individuals with insulin resistance, obesity, type 2
diabetes and other metabolic diseases are at an increased AD risk [12].
Independently of amyloid beta, APOE4 has a detrimental effect on metabolism.
Decades before the onset of AD, APOE4 carriers with normal cognition develop
abnormal brain glucose uptake, decreased cerebral blood flow, and disrupted
white matter integrity [13-15]. Systemically, APOE4 carriers exhibit elevated
fasting glucose and insulin levels leading to an increased risk of metabolic
syndrome and chronic low-grade inflammation [16, 17].
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1.3

Mild Traumatic Brain Injury Overview

The magnitude of traumatic brain injury continues to increase with
recent estimates suggesting that 3.8 million people sustain head injuries in the
United States every year. However, this number is probably much higher as
many go undiagnosed [18]. Traumatic brain injury is the leading cause of death
in people under the age of 45 in the western world [18], and has been coined the
“signature injury” of Iraq and Afghanistan conflicts, affecting 11-23% of those
deployed [19]. An approximated 1.6 million sport-related concussions occur in
the US annually, 50% of which go unreported [20, 21].

Mild traumatic brain injury is defined by the American Congress of
Rehabilitation Medicine as a “traumatically induced physiological disruption of
brain function” with the following criteria: normal structural imaging, loss of
consciousness of less than 30 minutes, and Glasgow coma scale score 13-15
[22, 23]. Most patients with mTBI are asymptomatic within a few weeks post
injury. However, 10-20% of patients continue to report detrimental symptoms for
months to years after the initial insult, including memory difficulties, issues with
attention and executive function, and increased depression and anxiety [23].

Brain vascular, structural and metabolic integrity are disrupted
months to years after traumatic brain injury. For example N-acetyl aspartate
4

(NAA) a brain metabolite and marker of neuronal health, is decreased in acute
and sub-acute periods of recovery indicating decreased health of neurons after
injury [24, 25]. Further, elevated choline, a marker of membrane disruption and
inflammation, indicates poor outcome after brain injury. Additionally, elevated
choline during the chronic period of injury recovery is indicative of gliosis. [26].
Along with this, cerebral blood flow (CBF) exhibits regional abnormalities in rats
8 months post injury [27] and humans 2 years post injury [28]. White matter
integrity (indexed by fractional anisotropy (FA)) has been shown to be affected
regionally after mTBI. Regions that exhibited decreased FA up to, and beyond 3
months post injury, were predictive of post-concussion syndrome, post-traumatic
stress and depression [29]. There are many long-term symptoms of mTBI that
overlap with AD symptomology, making it a risk factor for developing the disease
including reduced cerebral blood flow [13, 28], neuroinflammation [30, 31] and
barrier disruption [32, 33] among others.

1.3.1 Role in Alzheimer’s Disease and Dementia

Although there is a complex interaction between genetic and
environmental risk factors that trigger the development of neurodegenerative
diseases, trauma to the central nervous system is one of the most consistent
factors that initiates the cascade resulting in Alzheimer’s Disease (AD) and other
dementias [34]. Multiple epidemiological studies have pinpointed mTBI as a risk
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factor for late life dementia, especially AD [4, 35, 36], with meta-analyses
supporting this increased risk, especially in men [37].

There are multiple pathological processes that link neurotrauma
with neurodegeneration, for example, cerebrovascular damage. mTBI and AD
both show reduced cerebral blood flow. mTBI shows reduced CBF years after
injury [28], and those with the APOE4 allele exhibit reductions in CBF decades
prior to the onset of AD [13]. Along with this, neuroinflammation [30, 31], edema
[38, 39] and blood-brain barrier breakdown [32, 33] are commonalities between
the two.

mTBI and AD also share a commonality in that there are no
successful pharmacological treatments. For AD, drug trials have had a 99%
failure rate [40], with a 100% failure rate in TBI [41]. As pharmacological
interventions continue to fail, new preventative measures are being studied to
protect against TBI and prevent or delay the onset of AD. This includes targeting
the gut microbiome with a healthy diet [42, 43].

1.4

Gut Microbiome and the Gut-brain Axis
The gut microbiome consists of trillions of bacteria that inhabit our

gut and play a large role in overall health of the host [44]. These trillions of
bacteria have co-evolved with the host over thousands of years creating a
6

symbiotic relationship that is extremely intricate in nature [45, 46]. The primary
phyla that inhabit the gut include Firmicutes, Bacteroidetes Actinobacteria,
Verrucomicrobia and Proteobacteria [47]. However, a “healthy” gut microbiome
does not hinge on the presence of specific groups of bacteria but rather on
diversity and richness, leading to the presence of a greater repertoire of
metabolic functions [48].

The gut microbiome confers many benefits to the host including
strengthening of gut integrity [49], energy harvesting [50], pathogen protection
[51] and regulation of immunity [52]. Disruption of these mechanisms through an
imbalance of microbial composition can cause dysbiosis [44]. A dysbiotic
microbiome is associated with various diseases, most typically featuring a
change in diversity, loss of beneficial bacteria and/or an overgrowth of harmful
bacteria [53]. However, because the composition of the microbiome is subject to
influences from the host and environment, it is easily manipulated by factors
such as diet [44].

Current research suggests that host diet is able to heavily influence
the gut microbiome, with diet induced changes occurring as early 24 hours [54].
Shaping of the microbiome is subject to the availability of carbohydrates found in
dietary fiber that are accessible for microbial fermentation [44]. In a typical
western diet (high fat/high sugar), microbial accessible carbohydrates are
substantially reduced. This leads to altered composition and metabolic activity of
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the gut microbiome, which is now suspected of contributing to the epidemic of
chronic illnesses, including obesity and type II diabetes [55].

Dietary fiber consumption has been found to reverse these
changes in composition and metabolic activity through microbial fermentation.
Dietary fiber selects for increased levels of beneficial bacteria which leads to
increased levels of vital microbial metabolites such as short chain fatty acids
(SCFAs) [56]. SCFAs are known to positivity modulate glucose and lipid
metabolism as well as play a role in inflammation and a multitude of other
processes system wide [57]. SCFAs include acetate, butyrate and propionate
which are present in the colon in a ratio of around 3:1:1 [58]. However, diet can
modify this ratio to be anywhere between 3:1:1 and 1:1:1/2 [59]. Although only a
fraction of the colon derived SCFAs reach the circulation and peripheral tissues,
SCFAs can reach the brain and are known to play a role in the gut-brain axis
through regulation of the blood brain barrier, neuroprotection and neurogenesis
[57]

The gut-brain axis (GBA) is the avenue for bi-directional
communication between the brain and gut microbiome [60]. This bi-directional
communication implies a key role for the gut microbiome to regulate host
metabolism, immune and vascular systems, as previously mentioned. The
microbiome also influences the central nervous system by way of nerves,
through transmission of signals from the gut to the brain, and vice versa, in
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heathy and diseased states [60]. Recently, the gut-brain axis has been a topic of
investigation in mitigating symptoms after mTBI and throughout AD
development.

1.4.1 Gut-brain axis in Alzheimer’s Disease

The gut microbiome has been implicated in AD as it plays a critical
role in modulating immune function, blood brain barrier permeability and amyloid
beta clearance [61, 62]. In a dysbiotic state, which is present in AD, the gut
microbiome has negative impacts on the aforementioned factors.

Recently, studies have implied a possible association of the gut
microbiome with the amyloid beta pathway. Germ free mice with familial AD
mutations have reduced amyloid beta pathology, implicating the microbiome in
amyloid beta biology, and thus AD [63]. A variety of taxa are affected in those
with mild AD, including decreased levels of beneficial bacteria such as
Bifidobacterium. These changes in the microbiome were strongly correlated with
amyloid beta load [64].

Evidence also points to disturbances in the gut-brain axis
contributing to neuroinflammation. For example, bacteria naturally produce
lipopolysaccharides (LPS), an endotoxin, that can enter circulation when there is
a permeable gut barrier, which is present in AD. These molecules start
accumulating systemically and in the brain, which potentially causes age-related
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inflammatory changes [65]. Circulating LPS has been linked to increased
amyloid beta accumulation, reduced cognitive functions and increased proinflammatory cytokine levels, triggering neurodegeneration [66]. The link
between inflammatory metabolites produced by the gut microbiome clearly has a
role in the inflammation present in AD.

The blood brain barrier is confirmed to be damaged in patients with
AD. A damaged blood brain barrier is associated with learning and memory
deficits, as well as decreased CBF [67]. An imbalance of the receptors that
modulate influx and efflux within the blood brain barrier has a significant role in
the accumulation of amyloid beta and neuroinflammation [68]. Impairment of the
gut barrier allows LPS and other inflammatory cytokines to enter the systemic
circulation. Due to the imbalance of receptors at the blood brain barrier, proinflammatory cytokines and LPS enter the brain and trigger inflammation by
activating microglia and astrocytes [69]. Because metabolites such as SCFAs
play a role in microglial function and barrier integrity [70], this implicates the gut
microbiome in influencing AD pathogenesis through microglia activation,
enhanced neuroinflammation and barrier permeability.

In summary, when the microbiome is dysbiotic, pathogenic
organisms prevail over normal commensals [71]. These pathogenic
microorganisms interact with increased intestinal and blood brain barrier
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permeability to secrete metabolites that that cause inflammation and impact
mechanisms related to the pathogenesis of AD [72].

1.4.2 Gut-brain axis in mTBI

The gut microbiome is a relatively new topic of interest in TBI
research. Preliminary studies in rodents have shown that in the acute phase of
injury the gut microbiome becomes dysbiotic, with reductions in putatively
beneficial bacteria [73]. The running hypothesis is that neurotrauma induces
increased intestinal permeability and alters the gut microbiota which causes a
systemic immune response. This, combined with activated microglia from the
initial insult, causes persistent neuroinflammation [73-77]. The effects of
neurotrauma radiate to the intestine, making the gut microbiome an emerging
target to protect against the secondary injury cascade [78].

Two recent studies acutely analyzing the gut microbiome after TBI
showed similar results. The gut microbiome showed significant differences in
genus and species level taxa one day post-injury (d.p.i) with the lowest
Firmicutes to Bacteriodetes (F/B) ratio occurring one d.p.i [73, 79]. Gut
microbiome composition past the acute phase of traumatic brain injury has yet to
be characterized. This leaves a pivotal gap in the knowledge pertaining the longterm changes in gut microbial structure after the initial injury. In models of spinal
cord injury and ischemic stroke, gut dysbiosis persisted and in some cases
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increased (in spinal cord injury) up to 4 weeks post-injury [80, 81]. This gives a
good indication that head/neck trauma induces long lasting dysbiosis in the gut
microbiome after injury.

As stated above, SCFA levels are also known to be influenced by
the gut microbial composition and play a role in metabolism and inflammation
system wide [82]. There is a lack of data relating to SCFA levels after mTBI,
however, in spinal cord injury butyrate producers are decreased [83].
Supplementation with SCFA in a mouse model of severe TBI showed reduced
microglial activation, increased blood brain barrier integrity and improved spatial
memory [84].

It is also known that the gut microbiome plays a regulatory role in
many aspects of the brain, including immune processes such as microglial
maintenance and the production of important metabolites such as butyrate,
which helps promote blood brain barrier integrity [85]. A more intact barrier is
protective of cerebral blood flow [86]. Since SCFAs are produced by the
microbiome, this implicates a role in vascular integrity as well. Diet specific gut
microbiome populations were also recently found to be associated with
differences in white matter integrity [87]. However, there remains to be a paucity
of data pertaining to how the gut microbiome affects brain vascular, structural
and metabolic integrity and neuroinflammation in the context of injury
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1.5

Prebiotics
Prebiotics are a class of non-digestible carbohydrates that

stimulate the growth of beneficial bacteria. A proposed definition by Bindels et
al., states: “a non-digestible compound that, through its metabolization by
microorganisms in the gut, modulates composition and/or activity of the gut
microbiota” [88]. In order for a compound to be considered a prebiotic it must
meet these specifications: (i) resistant to pH of stomach, not hydrolyzed by
mammalian enzymes, not absorbed in the gastrointestinal tract, (ii) fermented by
intestinal microbiota, (iii) growth/activity of intestinal bacteria can be selectively
stimulated to improve the hosts health [89].

Prebiotics, colloquially referred to as fiber, are found in foods such
as fruits, vegetables, legumes and whole grains. These foods typically contain a
mixture of soluble and insoluble fiber, which have various roles. Soluble fiber
forms a gel when interacting with water and can be fermented into beneficial
metabolites by the gut microbiome such as SCFAs. Insoluble fiber doesn’t
dissolve in water and is minimally fermented, but helps in relieving constipation
[90]. The benefits of soluble and insoluble fiber tend to overlap, including
improved gut permeability, reduced pathogenic bacteria, beneficial modulation of
the immune system, reduction in cholesterol and cardiovascular disease,
intestinal health and so on [91].
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There is literature showing the effects of prebiotics on the gut-brain
axis in TBI and AD. In a recent study, young male mice were given a moderate
TBI, and those fed prior to the injury with various supplements of fruit or
vegetable blends had reduced neuroinflammation and improved functional
recovery, compared to those fed a control diet [42].

Additionally, a previous study in our lab aimed to understand the
effects of prebiotic intervention in a mouse model of AD. The mouse model has a
C57BL/6 background that overexpresses human amyloid beta via 5 familial-AD
(5xFAD) mutations and expresses the knocked-in human APOE4 (E4FAD) gene.
E4FAD mice were fed inulin, a prebiotic, or a control diet containing cellulose.
Mice fed inulin exhibited a beneficially altered gut microbiome, increased
microbial metabolism via gut-brain axis metabolites (SCFAs), enhanced glucose
metabolism and reduced inflammatory gene expression in the hippocampus [43].
As asymptomatic APOE4 carriers show metabolic deficits decades before
disease progression, this shows that inulin is a viable preventative treatment
option. Collectively, prebiotics have a vast array of benefits that show promise in
mitigating mTBI and AD risk in mouse models.

It must be noted that transition of preclinical dietary research into
human clinical trials may pose some road-blocks that should be taken into
account [92]. For example, compliance is based on tolerance of the diet or food.
If a high fiber diet is not well tolerated, retention of subjects will decrease [92].
Along with this, other hardships include considering baseline nutritional status of
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participants, defining appropriate control groups and creating effective blinding
procedures [92]. Although there is still work to be done transitioning pre-clinical
studies into clinical trials, understanding the weaknesses is the first step in
optimizing the process.

1.5.1 Inulin
For our studies, as stated above, we will use inulin, a soluble and
fermentable dietary fiber. It has been well documented that inulin increases
SCFAs and beneficial bacteria such as Bifidobacterium species [43, 93]. There
are some gastrointestinal effects reported from inulin intake including diarrhea,
bloating, cramping and excess flatulence. These side effects are generally
present at intakes greater than 40g/day with variation among individuals. A daily
dose of 2.5-10g/day is recommended to promote a healthy microbiome in
humans [94].

Inulin has been vastly studied in both humans and animal models
and has overall produced beneficial effects. Various inconsistencies may be
attributed to different doses of inulin given in each study. In humans, inulin has
been shown to reduce cholesterol in obese subjects [95] and beneficially impact
blood glucose and lipids in type II diabetics [96]. Animal models have
demonstrated anti-carcinogenic effects and anti-inflammatory effects in the colon
[97].
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There is not as much research on inulin’s effects in the brain.
However, as mentioned above, a previous study in our lab showed E4FAD mice
fed inulin exhibited an altered gut microbiome, increased microbial metabolism
via gut-brain axis metabolites (SCFAs), enhanced glucose metabolism
systemically and reduced inflammatory gene expression in the hippocampus
[43]. These results are suggestive of the fact that inulin produces beneficial
effects systemically, that also reach the brain. Since we have investigated the
effects of inulin in APOE4 mice, we want to better understand the effects of inulin
on the other APOE alleles, starting with APOE3, as it has the highest prevalence
in the population. This will give us insight into how each APOE allele responds to
specific diets, highlighting the importance of precision nutrition.

Additionally, because it is now known that gut microbiome
dysbiosis occurs after TBI, modulation of the gut microbiome by diet may be
critical to restore balance to the microbiome and thus mitigate the secondary
injury cascade following injury. Interventions supporting gut health and barrier
function could be a mechanism which leads to a “cushioning” of the injury
cascade [98]. As less than 5% of all age groups in the USA meet fiber
requirements, this postulated “cushioning” effect will only be achieved through
increased fiber intake. Based on previous studies, we believe inulin is a good
candidate to investigate if increased fiber intake is protective of, or can mitigate,
the secondary injury cascade following mTBI.
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2.1

Abstract
The goal of the study was to identify the potential nutrigenetic

effects to inulin, a prebiotic fiber, in mice with different human apolipoprotein E
(APOE) genetic variants. Specifically, we determined the similar and different
responses to inulin for the potential modulation of the systemic metabolism and
neuroprotection via gut-brain axis in mice with human APOE 3 and 4 alleles.
We performed experiments with young mice expressing the human APOE3
(E3FAD mice) and APOE4 gene (E4FAD mice). We fed mice with either inulin or
control diet for 16 weeks starting from 3 months of age. We determined gut
microbiome diversity and composition using16s rRNA sequencing, systemic
metabolism using in vivo MRI and metabolomics, as well as blood-brain barrier
(BBB) tight junction expression using Western blot. In both E3FAD and E4FAD
mice, inulin altered the alpha and beta diversity of the gut microbiome, increased
beneficial taxa of bacteria (Lactobacillus and Prevotella), and elevated cecal
short chain fatty acid and hippocampal scyllo-inositol (an Aβ inhibitor). However,
E3FAD mice had altered metabolism related to tryptophan and tyrosine, while

E4FAD mice had changes in the tricarboxylic acid cycle, pentose phosphate
pathway, and bile acids. Differences were also found in levels of brain
metabolites related to oxidative stress reduction, and levels of Claudin-1 and
Claudin-5 BBB tight junction expressions between the two groups. We found that
inulin had many similar beneficial effects in the gut and brain for both E3FAD
and E4FAD mice, which may be protective for brain functions and reduce risk for
neurodegeneration, such as Alzheimer’s disease. E3FAD and E4FAD mice also
had distinct responses in several metabolic pathways, suggesting an APOEdependent nutrigenetic effects in modulating systemic metabolism and
neuroprotection. Our findings indicate the importance of precision nutrition as
response to diet may be highly dependent on the host’s genotype.

2.2

Introduction
Nutrigenetics refers to the potential impacts of diet that may be

driven by individual’s genetic background [99]. In contrast to the “one-size-fitsall” assumption, it has been suggested that the heterogeneous response of
gene variants to nutrients and dietary components may need to be taken into
consideration in the nutritional studies [99].

The goal of the study is to understand the nutrigenetic effects of
the Apolipoprotein E gene (APOE) variants to prebiotic inulin. ApoE is a protein
involving cholesterol and lipid transports [6]. Humans possess three genetic
isoforms of APOE – APOE2, APOE3, and APOE4 – that confer differential risk
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for developing metabolic syndrome and neurodegenerative disorders [100].
Specifically, APOE4 carriers have higher risk than the other two allele carriers for
developing disorders such as diabetes and Alzheimer’s disease [100]. They
showed early signs of impairments in mitochondrial function, tricarboxylic acid
cycle activity, glucose oxidative metabolism, and cognitive capability [13, 101].
Further, recent studies showed that APOE4 carriers are also associated with
alternated and imbalanced gut microbiota (a.k.a., dysbiosis), which in turns
exacerbates the systemic inflammation and metabolic dysfunction [43, 102, 103].

In a previous study, we showed that inulin, a prebiotic fiber, is
effective in restoring systemic metabolism, enhancing gut microbiome balance,
reducing neuroinflammation, and increasing levels of short chain fatty acids
(SCFAs), tryptophan-derived metabolites, bile acids, glycolytic metabolites, and
scyllo-inositol (inhibiting Aβ aggregation) in an APOE4 mouse model (E4FAD
mice) [43]. In this study, our goal is to further determine if inulin has nutrigenetic
effects for mice with different human APOE variants. In particular, we wanted to
identify if mice with human APOE3 gene (E3FAD mice; neutral AD risk) would
have different responses to inulin compared to the E4FAD mice.

As APOE4 carriers develop early deficits in brain and systemic
metabolism, it would be important to identity interventions that may mitigate the
deficits at early stage [13, 101]. Therefore, an additional goal of the study was to
determine the effects of inulin as a preventive intervention. We fed young mice
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(3 months of age) with either inulin or control diet for 16 weeks. We determined
the effects of inulin on gut microbiome diversity and composition, brain and
systemic metabolism, as well as blood-brain barrier (BBB) tight junction
expression in the study.

2.3

Methods

2.3.1 Animals and Study Design
We used a C57BL/6 mouse model which accumulates human Aβ42
due to co-expression of 5 familial-AD (5xFAD) mutations in conjunction with
human targeted replacement APOE (ε4 in the E4FAD line and ε3 in the E3FAD
line). Each mouse was genotyped by Transnetyx Inc. (Cordova, TN, USA) to
verify the genotype after weaning. The mice were separated into 4 groups:
E3FAD-control, E3FAD-inulin, E4FAD-control, and E4FAD-inulin. We
determined the sample size via power analysis with a comparison at a 0.05 level
of significance and a 90% chance of detecting a true difference of each
measured variable between groups; N= 15 per group (male= 7; female = 8) for
gut microbiome experiments, a subset of mice (N= 8/group; male: female= 1:1)
for the brain imaging and SCFAs experiments, and the other subset of mice (N=
7/group) for the BBB tight junction measurements. The prebiotic inulin diet
contained 8% of fiber from inulin, and the control diet contained 8% of fiber from
cellulose (Table 2-1). We started to feed mice at 3 months of age and fed them
for 16 weeks (until they reached 7 months of age). As we previously reported
that the mice had not developed severe AD pathology nor cognitive impairment
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at 7-8 months of age [43], the feeding period allowed us to determine the effects
of inulin on systemic metabolism as a preventive intervention. Both the inulin
diet and the control diet are modifications of TestDiet’s AIN-93G Semi-Purified
Diet 57W5 (cellulose:9GLK; inulin:9GLL). Details of the composition of the
control (cellulose) and inulin diets can be found in Table 2-1. Evidence shows
that 8% inulin increases short chain fatty acids and improves enzyme activity in
the mouse cecum compared to 4% inulin [104]. In addition, studies indicate that
8% inulin intake (40 g fiber per day) is the maximum amount for western humans
to tolerate without side effects [105]. Each mouse was single housed (to avoid
feces exchange) with ad libitum access to food and water. Food intake and body
weight were recorded biweekly. The study was approved by the Institutional
Animal Care and Use Committee (IACUC) at our institution.

2.3.2 Fecal Sample Collection and Gut Microbiome Analysis

2.3.3 Fecal DNA Amplification
Fecal samples were collected from all the mice (N= 15/group) and
frozen at -80˚C until further use. A PowerSoil DNA Isolation Kit (MO BIO
Laboratories, Inc.) was used for fecal DNA extraction, according to the
manufacturer’s protocol [106]. First stage amplifications were performed followed
by the second-stage PCR amplification with Access Array Barcode Library for
Illumina Sequencers. The gene amplicon sequence data generated as part of
this study have been submitted to the NCBI BioProject database.
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2.3.4 Microbial Analysis

Forward and reverse reads were merged using PEAR [107].
Sequences were then trimmed based on quality scores using a modified Mott
algorithm with PHRED quality threshold of p = 0.01, and sequences shorter than
300 bases after trimming were discarded. QIIME v1.8 was used to generate
OTU tables and taxonomic summaries for all phyla, classes, orders, families,
genera, and species present in the dataset [108]. Shannon and Bray-Curtis
indices were calculated with default parameters in R using the vegan library
[109]. The rarefied species data, taxonomic level 7, were used to calculate both
indices. Significant difference among tested groups was determined using the
Kruskal-Wallis one-way analysis of variance. The group significance tests were
performed on the rarefied species data, taxonomic level 6 (genus), using the
group_significance.py script within the QIIME v1.8 package.

2.3.5 In vivo Brain Metabolites Measurements
1H-MRS

was conducted on a 7T ClinScan MR scanner (Siemens,

Germany) at the Magnetic Resonance Imaging & Spectroscopy Center at our
institution. MRS was utilized to measure metabolites in the hippocampus, as we
previously reported [43]. N= 8 per group (male: female=1:1) were used for the
experiment. The following metabolites were measured: alanine, total choline,
glutamate-glutamine complex, myo-inositol, scyllo-inositol, lactate, NAA,
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phosphocreatine, total creatine, and taurine using the LCModel software to find
the absolute concentration of the metabolites [110].

2.3.6 Short Chain Fatty Acid Measurements
After euthanizing the mice, we collected cecal and whole blood
samples and sent them to Metabolon Inc. (Durham, NC) for SCFAs analysis.
The same group of mice from the 1H-MRS study (N= 8/group) were used for the
experiment. The unit of cecal samples was g/g and the unit of blood samples
was ng/mL. Samples were processed by liquid chromatography/mass
spectrometry (LC-MS/MS) for acetate, propionate, and butyrate. Samples were
labelled with internal standards and homogenized in an organic solvent. They
were then centrifuged followed by an aliquot of the supernatant used to
derivatize to form SCFAs hydrazides. This reaction mixture was subsequently
diluted, and an aliquot was injected onto a C18 column in Agilent 1290 UHPLC
interfaced to an AB Sciex QTrap 5500 LCMS/MS system with electrospray
ionization operating in negative mode using electrospray ionization. The raw
data were analyzed by AB SCIEX software (Analyst 1.6.2).

2.3.7 Non-targeted Metabolomics Profiling
The whole blood and brain tissue (from cortex and hippocampus)
were processed for metabolomics profiling at Metabolon Inc. as well.
Metabolon’s standard solvent extraction method was used to prepare the
samples, which were then equally split for analysis via LC/MS or gas
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chromatography/mass spectrometry (GC/MS) using their standard protocol
[111]. Non-targeted UPLC-MS/MS and GC-MS analyses were performed at
Metabolon, Inc.

2.3.8 Tight junction measurements
2.3.9 Brain Capillary Isolation
Brain capillaries were isolated from another subset of mice (N=
7/group) as described previously [112]. Isolated capillary pellets from each
group were resuspended in CelLyticTM lysis buffer (Millipore-Sigma) containing
cOmpleteTM protease inhibitor cocktail (Roche, Mannheim, Germany).
Suspensions were homogenized, centrifuged (30,000 g for 30 min; 95,000 g for
2h; 4 °C) in a fixed-angle rotor (TLA 100.2; Beckman Coulter, Indianapolis, IN,
USA), resuspended and frozen at -20°C until further analysis.

2.3.10 Western Blotting
Sample protein concentrations were determined by Bradford
assay. Membranes were blocked and incubated with primary antibody overnight
(β-actin: 1 mg/ml, ab8226, Abcam, Cambridge, MA, USA; Claudin-1: 0.5 mg/ml,
ab56417, Abcam, Cambridge, MA, USA; Claudin-5: 0.5 mg/mL, 35-2500,
Thermo Fisher Scientific; Occludin: 0.5 mg/mL, 71-1500, Thermo Fisher
Scientific). Membranes were washed and incubated with horseradish
peroxidase-conjugated ImmunoPureTM secondary IgG (1:10,000; Pierce,
Rockford, IL, USA) for 1 h at room temperature. Protein bands were visualized
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using Pierce SuperSignalTM West Pico and West Femto chemiluminescent
substrates (Thermo Fisher Scientific) using a ChemiDocTM XRS imager (Bio-Rad
Laboratories, Hercules, CA, USA). Optical density was measured with ImageLab
software (v.4.6.9; Bio-Rad Laboratories). Four replicate blots were obtained from
pooled tissue of the seven mice in each group.

2.3.11 Statistical Analysis
All statistical analyses were completed using GraphPad Prism
(GraphPad, San Diego, CA, USA). We performed a 2-way ANOVA to
determinate the differences between groups. To determine which comparison
the statistical differences were coming from we used post hoc Tukey’s multiple
comparisons test. For Metabolon, log transformations were conducted followed
by ANOVA for identification of biochemicals that were significantly different
between groups. Between group differences were assessed with p-values and qvalues (with the Benjamini Hochberg FDR) with a p-value or q-value (when
applicable) less than 0.05 showing statistical significance.

2.4

Results

2.4.1 Inulin maintains bodyweight but alters the gut microbiome of the E3FAD
and E4FAD mice
We first determined if the inulin diet changed the food intake and
bodyweight of the mice compared to the controls. We found that there was no
difference in either food intake (Fig. 2-1A) or body weight (Fig. 2-1B) between
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the inulin- and the control-fed mice after 16 weeks of feeding. We further looked
at the gut microbiome and found that there was a significant decrease in αdiversity in E3FAD-inulin mice (Gausian link function results, p < 0.001) (Fig. 21C) and in E4FAD-inulin mice compared to their controls (Gausian link function
results, p = 0.019) (Fig. 2-1D). This shows species richness and evenness were
decreased within each group following inulin treatment. Similarly, E3FAD- and
E4FAD-inulin mice had significant differences in beta-diversity compared to the
controls (E3FAD mice: ANOSIM R statistic = 0.877, p-value = 0.001) (Fig. 2-1E)
(E4FAD mice: ANOSIM R statistic = 0.454, p-value = 0.001) (Fig. 2-1F). This
shows the ratio of species was different between the two groups following inulin
treatment.

Significant changes were also observed in numerous bacterial taxa
due to the beneficial effects of the prebiotic inulin. Table 2-2 shows the fold
change between the group comparison; red indicates significant increases while
green indicates significant decreases (p < 0.05). Both E3FAD-inulin and E4FADinulin mice had decreased Turicbacter, but increased Lactobacillus and
Prevotella, compared to their respective control groups. Moreover, inulin
increased Bifidobacterium in E3FAD mice compared to its control. These results
indicate that the prebiotic inulin alters the gut microbiota in E3FAD and E4FAD
mice in a different manner.
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2.4.2 Inulin increased SCFAs in E3FAD and E4FAD mice
Both E3FAD-inulin and E4FAD-inulin mice showed a significant
increase in SCFAs levels in the cecum, including acetate (Fig. 2-2A), propionate
(Fig. 2-2B), and butyrate (Fig. 2-2C). In the blood samples, we found that
acetate (Fig. 2-2D) was also significantly higher in the E4FAD-inulin group.
Blood propionate (Fig. 2-2E) and butyrate (Fig. 2-2F) were trending higher in the
Inulin-fed groups though did not reach statistical significance.

2.4.3 Inulin altered systemic metabolism differently in the E3FAD and E4FAD
mice
From the blood samples, we found that inulin induced different
patterns of metabolic changes among the E3FAD and E4FAD mice. Inulin
increased tryptophan-related metabolites while decreasing tyrosine-related
metabolism in the E3FAD-inulin compared to the E3FAD-control mice (Table 23). The tryptophan metabolites included indoleacrylate, indolepropionate (IPA),
serotonin, indoleacetylglycine, and N-acetyltryptophan. Tyrosine metabolites
included phenol sulfate, phenol glucuronide and p-cresol glucuronide. In the
E4FAD-inulin mice, only changes in indoleacrylate, IPA and p-cresol glucuronide
were seen compared to the E4FAD-control mice.

In contrast, E4FAD-inulin mice had significant changes in
metabolism involved in the pentose phosphate pathway, TCA cycle, and primary
and secondary bile acids. Table 2-3 shows that E4FAD-inulin mice had
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significantly increased levels of ribose, ribitol, ribonate, ribulose, arabitol,
arabonate, and sedoheptulose in pentose metabolism compared to E4FADcontrol. In TCA Cycle metabolites, riboaconitate, isocitric lactone, succinate,
fumarate, and malate increased in the E4FAD-inulin mice. Inulin also increased
bile acid and their associated metabolites in E4FAD-inulin mice compared to
E4FAD-control mice, including cholate and beta-muricholate (primary bile acids),
and deoxycholate, ursodeoxycholate, 7-ketodeoxycholate and ursocholate
(secondary bile acids). On the other hand, in the E3FAD-inulin mice, we found
increases only in ribose (pentose metabolism) and alpha-ketoglutarate (TCA
cycle) compared to the E3FAD-control mice.

2.4.4 Inulin changes brain metabolites in the E3FAD and E4FAD mice

We further looked at the effect of the inulin on brain metabolites.
We found that inulin reduced the level of 5-hydroxyindoleacetate in E4FAD-inulin
mice, but not in the E3FAD mice (Fig. 2-3A). Inulin increased acetylcarnitine
(C2) concentration in the inulin-fed groups, though only reached statistical
significance in the E3FAD-inulin group (Fig. 2-3B). In contrast, myo-inositol
concentration decreased in the inulin-fed mice, but only reached statistical
significance in the E4FAD-inulin mice (Fig. 2-3C). Scyllo-inositol level increased
in both E3FAD-inulin and E4FAD-inulin mice compared to their controls (Fig. 23D). The increase in scyllo-inositol from the brain tissue was confirmed by in vivo
brain imaging using 1H-MRS. Figure 2-3E shows the voxel that was used for
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obtaining the spectra and a representative spectrum is shown in Figure 2-3F. An
arrow indicates the position of scyllo-inositol (3.34 ppm). We observed the level
of scyllo-inositol to be significantly higher in the hippocampus in both E3FADand E4FAD-inulin mice relative to their controls (Fig. 2-3G).

2.4.5 Inulin has differential effects on blood-brain barrier tight junction protein
levels in the E3FAD and E4FAD mice

We have previously reported that dietary inulin reduces
neuroinflammation in the E4FAD mouse model [43]. To examine the effect of
inulin on the brain microvasculature, we compared tight-junction protein
expression levels in brain capillaries isolated from E3FAD-control and E4FADcontrol mice with E3FAD-inulin and E4FAD-inulin mice (Fig. 2-4A). Inulin did not
significantly alter occludin protein levels in E3FAD mice or E4FAD mice but
occludin protein levels were significantly lower in E4FAD-inulin mice compared
to E3FAD-control mice (p = 0.0045) (Fig. 2-4B). Further, Claudin-1 protein
expression levels were significantly higher in E4FAD-control mice compared to
E3FAD-control mice (p = 0.0012) (Fig. 2-4C). Inulin did not alter Claudin-1
protein expression levels in E3FAD mice whereas Claudin-1 levels were
significantly lower in E4FAD-inuiln mice compared to E4FAD-control mice (p =
0.0036). E3FAD-inulin mice also had a significantly higher protein expression for
Claudin-5 compared to E3FAD-control mice (p = 0.0122) (Fig. 2-4D). Likewise,
Claudin-5 protein expression levels were significantly higher in E3FAD-control
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mice compared to E4FAD-inulin mice (p = 0.0026). These values indicate that
inulin affects tight-junction proteins differently in E3FAD and E4FAD mice.

2.5

Discussion
In this study, we demonstrated that inulin had systemic benefits for

both E3FAD and E4FAD mice. We further demonstrated that the E3FAD and
E4FAD mice had very different responses to inulin, indicating a nutrigenetic
effect depending on APOE genotype. Figure 2-5 summarizes the similarities and
differences of E3FAD and E4FAD mice responding to inulin.

The similar effects that inulin had on E3FAD and E4FAD mice
included the alpha- and beta- diversity of the gut microbiome, increased the
abundance of Lactobacillus and Prevotella taxa, and reduced abundance of
Tuicibacter taxa (Fig. 2-5; middle column). In both groups, inulin also increased
the cecal SCFAs and scyllo-inositol level in the hippocampus. Lactobacillus and
Prevotella are known to produce SCFAs including acetate, butyrate, and
propionate [113-115]. This is consistent with our findings that SCFAs were
increased in the inulin-fed mice, specifically acetate in the E4FAD mice. Though
being present mostly in the periphery system [57, 116], SCFAs have been
shown to have a dramatic impact on brain vascular and metabolic function [117].
Specifically, butyrate was shown to be able to restore BBB tight junctions and
consequently restored BBB function [118], which is consistent with our results of
changes in Claudin-5 expression in the BBB of E3FAD mice. Further, scyllo30

inositol was found to be increased in hippocampus in vivo and from the brain
extracts. Scyllo-inositol has been shown to inhibit Aβ42 aggregation in both
animal and clinical trials [119, 120], suggesting that inulin might be able to
reduce AD pathology when the mice get older.

Inulin induced different responses between the E3FAD (Fig. 2-5,
left column) and E4FAD mice (Fig. 2-5, right column). Notably, E3FAD mice
had altered metabolic pathways in the periphery related to tryptophan and
tyrosine, while E4FAD mice had changes related to TCA, PPP and bile acids.
Inulin increased Bifidobacterium in the E3FAD mice but showed no change in
the E4FAD mice. There were also different changes in brain metabolites, and
levels of Claudin-1 and Claudin-5 expressions between the two groups.

Tryptophan and tyrosine metabolism enhance the nervous system.
Tryptophan is an essential amino acid and is the precursor of serotonin. Indole3-propionic acid, a tryptophan-derived metabolite, can inhibit Aβ fibril formation
in neurons and neuroblastoma cells [121]. Metabolites that play a role in tyrosine
metabolism including phenol sulfate, phenol glucuronide, and p-cresol
glucuronide were found to be lower in the inulin-fed mice, suggesting that inulin
decreases inflammation in the E3FAD mice [122]. The higher abundance of
Bifidobacterium found in the E3FAD mice compared to E4FAD mice suggests a
reduced level of anxiety [123], which is consistent with our previous findings that
E3FAD mice had lower anxiety compared to the E4FAD mice [124]. In contrast,
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E4FAD mice had enhanced TCA, PPP and bile acid metabolism compared to
E3FAD mice. Both TCA and PPP pathways involve energy production through
mitochondria [125]. Research shows that the PPP regulates the chronic
neuroinflammation in the brain and may therapeutically improve
neurodegeneration in the brain such as Parkinson’s disease [125]. Further, bile
acids significantly impact pathways involved in host cholesterol, lipid and glucose
metabolism, and inflammation, and have the potential to alter the host immunity
[126] and circadian rhythms [127]. Collective evidence also shows that primary
and secondary bile acid metabolism regulates the innate immune system by
activation of bile acid activated receptors [128] and adaptive immune system by
regulation of Th17 cells and regulatory T cells [129]. These findings are
consistent with neuroimaging markers, showing that E4FAD mice had decreases
in myo-inositol [130, 131], an inflammatory marker, in the hippocampus.

In brain metabolites, we found increased acetylcarnitine in E3FADinulin mice. Acetylcarnitine has been well studied to prevent oxidative stress and
aging [132], suggesting inulin may reduce oxidative stress for the E3FAD mice.
In contrast, we found reduced 5-hydroxyindoleacetate in the E4FAD-inulin mice.
5-hydroxyindoleacetate has been shown to be related to aggressive behaviors
and toxification by affecting brain glutathione-S-transferase [133, 134].
Therefore, inulin might benefit the E3FAD mice by oxidative stress reduction,
while it might benefit the E4FAD mice by increasing detoxification in the brain
and lowering the risk for aggressive behavior development.
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Previous studies found that the ApoE4 genetic background is
associated with BBB dysfunction [93]. In the present study, we observed that
inulin differentially affects tight-junction protein expression levels in isolated brain
capillaries from E3FAD and E4FAD mice. Specifically, inulin decreased Claudin1 expression in E4FAD mice, while increasing Claudin-5 expression in E3FAD
mice. A previous study in a chronic stroke mouse model showed that increased
Claudin-1 protein expression is associated with leaky brain capillaries and an
endothelial proinflammatory phenotype [135]. Claudin-5 is the most enriched
tight junction protein and its dysfunction has been implicated in many
neurological disorders including AD, multiple sclerosis, depression, and
schizophrenia [136]. It is possible to abrogate disease symptoms in many of
these disorders by regulating levels of Claudin-5.

Though we studied the mice at pre-symptomatic stage, our study
implied that inulin may reduce risk for developing AD for both APOE3 and
APOE4 carriers. Emerging evidence further shows that AD is associated with
brain metabolic impairment [10], gut microbiota dysbiosis [64], and bile acid
profile alterations [137]. Further, tryptophan metabolism is also seen to be
altered in patients with AD [138], which impedes the capacity to inhibit Aβ fibril
formation in neurons and neuroblastoma cells [121]. The findings from the
current studies suggest that AD risk might be able to be mitigated with early
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interventions of inulin. Future studies will be needed to verify the speculation with
older animals.

In summary, we demonstrated that early interventions of inulin
would be beneficial for enhancing brain and systemic metabolism through gutbrain axis, and the responses to the inulin diet are APOE genotype-dependent.
Our findings indicate the importance of nutrigenetics and precision nutrition as
the responses to a diet may be highly dependent on the genotype of the host.
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Table 2-1. Diet composition.
Diet
Protein %
Carbohydrate %
Fat %
Fiber %
Energy (kcal/g)

Prebiotic Diet
18.2
67.8
7.1
8.0 (Inulin)
4.08
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Vehicle Control Diet
18.2
60.2
7.1
8.0 (Cellulose)
3.78

Table 2.1. Diet composition. Diet composition of the prebiotic and control
diet.
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Table 2-2. Gut microbiota taxonomy changed by inulin.
E3FAD
Taxonomy

Fold Change

E4FAD
Q value

Inulin
Ctrl

Fold Change

Q value

Inulin
Ctrl

Turicibacter

-2.11

2.96E-06

-0.47

0.03

Lactobacillus

+1.21

9.69E-04

+1.48

0.02

Prevotella

+1.48

1.11E-03

+1.78

2.17E-03

Bifidobacterium

+2.10

2.20E-06

0.11

0.95
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Table 2-2. Gut microbiota taxonomy changed by inulin. Taxonomic
differences at the genus level between E3FAD and E4FAD prebiotic and control
fed mice. q-values were calculated for each taxon along with each group with a
significant difference (q < 0.05). Fold change was calculated for each taxon of
each group. Red and green shaded cells indicate p ≤ 0.05 (red specifies that the
mean values are significantly higher for that comparison; green values
significantly lower)
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Table 2-3. Tryptophan and tyrosine metabolism, Pentose metabolism, TCA and
bile acid changes induced by inulin

Fold Change
Inulin
Ctrl
Pathway

Biochemical Name

E3FAD

E4FAD

Tryptophan
Metabolism

indoleacrylate
indolepropionate
serotonin
indoleacetylglycine

2.91
6.42
1.37
1.55

5.68
9.68
1.29
0.65

N-acetyltryptophan
phenol sulfate
phenol glucuronide

1.3
0.23
0.21

0.81
0.87
2.11

p-cresol glucuronide

0.08

0.14

ribose
ribitol
ribonate
ribulose/xylulose
arabitol/xylitol
arabonate/xylonate
sedoheptulose
isocitric lactone
alpha-ketoglutarate
succinate
fumarate
malate

1.67
0.99
1.46
1
0.87
1.22
0.82
1.28
1.73
1.03
1.23
1.24

1.41
2.01
2.08
1.37
2.67
1.36
1.68
1.73
2.53
2
1.6
1.44

cholate

1.06

10.92

beta-muricholate

1.82

16.81

deoxycholate

0.8

8.78

ursodeoxycholate

1.37

82.41

7-ketodeoxycholate

0.86

82.44

ursocholate

1.76

22.69

Tyrosine
Metabolism

Pentose
Metabolism

TCA Cycle

Primary Bile
Acid
Metabolism
Secondary
Bile Acid
Metabolism
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Table 2-3. Tryptophan and tyrosine metabolism, Pentose metabolism, TCA
cycle, and bile acid changes induced by inulin. A table showcasing the
metabolite changes in tryptophan and tyrosine metabolism, pentose metabolism,
TCA cycle, and bile acid metabolism due to the prebiotic inulin and differences
and differences between E3FAD and E4FAD mice in the blood. Welch's twosample t-test was performed. Heat map of statistically significant biochemicals
profiled when comparing groups are labeled as follows: Red and green shaded
cells indicate p ≤ 0.05 (red specifies that the mean values are significantly higher
for that comparison; green values significantly lower)
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Figure 2-1. Food intake, body weight and gut microbiome diversity.
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Figure 2-1. Food intake, body weight and gut microbiome diversity. Inulin
feeding did not change the (A) food intake and (B) body weight of the mice. Inulin
induced significant differences of the α-diversity in the (C) E3FAD and (D)
E4FAD mice, compared to their control littermates. Inulin also induces significant
differences in β -diversity in the (E) E3FAD and (F) E4FAD mice, compared to
their controls. N= 15/group. Data are presented as Mean ± SEM.
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Figure 2-2. Short chain fatty acids (SCFAs).
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Figure 2-2. Short chain fatty acids (SCFAs). Inulin significantly increased (A)
cecal acetate, (B) cecal propionate, and (C) cecal butyrate of the E3FAD and
E4FAD mice compared to their controls. For SCFAs in the blood, significantly
elevation was found in (D) acetate from the E4FAD-inulin group; (E) blood
propionate or (F) blood butyrate did not show changes in either of the E3FAD or
E4FAD mice. N= 8/group. Data are Mean ± SEM; ns = not significant (p  0.05),
*p < 0.05, **p < 0.01.
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Figure 2-3. Metabolite changes in brain tissue in response to inulin and
Scyllo-inositol levels in the hippocampus, fecal culture, and plasma.
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Figure 2-3. Metabolite changes in brain tissue in response to inulin and
Scyllo-inositol levels in the hippocampus, fecal culture, and plasma. (A) 5hydroxyindoleacetate was reduced in the E4FAD-inulin mice compared to the
E4FAD-control. (B) Acetylcarnitine (C2) was increased in the E3FAD-inulin mice
compared to E3FAD-control. (C) Myo-inositol was significantly lower in the
E4FAD-inulin mice compared to the controls. (D) Scyllo-inositol was elevated in
both E3FAD-inulin and E4FAD-inulin mice compared to their controls. (E) 1HMRS voxel on hippocampus. (F) A representative 1H-MRS spectrum, showing Nacetyl-aspartate (NAA), glutamate (Glu) and glutamine (Gln), creatine (Cr),
glycerophosphocholine (GPC) and phosphocholine (PCh), scyllo-inositol (Scyllo),
taurine (Tau), and myo-inositol (mI) in parts per million (ppm). (G) Scyllo-inositol
was dramatically increased in the hippocampus of E3FAD-inulin and E4FADinulin mice compared to E3FAD-control and E4FAD-control mice, respectively.
N= 8/group. Data are Mean ± SEM, ns = not significant (p  0.05), *p < 0.05, **p
<0.01, ****p < 0.0001.
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Figure 2-4. Western blot analysis of tight-junction protein expression
levels.

47

Figure 2-4. Western blot analysis of tight-junction protein expression
levels. (A) Representative Western blot for occludin (~55-65 kDa), claudin-1
(~23 kDa), and claudin-5 (~23 kDa). β-actin (~42 kDa) served as protein loading
control. Normalized protein expression levels for (B) Occludin, (C) Claudin-1,
and (D) Claudin-5 are given as fold change in percent (%). Values are
represented as Mean ± SEM for replicate blots (N = 4; pooled tissue from
E3FAD-Control (N = 7 mice), E3FAD-Inulin (N = 7 mice), E4FAD-Control (N = 7
mice), E4FAD-Inulin (N = 7 mice); *p < 0.0332; ** p < 0.0021; ***p < 0.0002.
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Figure 2-5. Summary of the similarities and differences of responses to
inulin between E3FAD and E4FAD mice.

Figure 2-5. Summary of the similarities and differences of responses to
inulin between E3FAD and E4FAD mice.
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3.1

Abstract
Mild traumatic brain injury (mTBI) has been shown to acutely alter

the gut microbiome diversity and composition, known as dysbiosis, which can
further exacerbate metabolic and vascular changes in the brain in both humans
and rodents. However, it remains unknown how mTBI affects the gut microbiome
in the chronic phase recovery (past one week post injury). It is also unknown if
injury recovery can be improved by mitigating dysbiosis. The goal of the study is
to fill the knowledge gap. First, we aim to understand how mTBI alters the gut
microbiome through the chronic period of recovery (3 months post injury). In
addition, as the gut microbiome can be modulated by diet, we also investigated if
prebiotic inulin, a fermentable fiber that promotes growth of beneficial bacteria
and metabolites, would mitigate dysbiosis, improve systemic metabolism, and
protect brain structural and vascular integrity when administered after 3 months
post closed head injury (CHI). We found that CHI given to male mice at 4 months
of age induced gut dysbiosis which peaked at 1.5 months post injury, reduced
cerebral blood flow (CBF) and altered brain white matter integrity. We also found
that Sham mice had transient dysbiosis peaking 24 hours after injury and then

normalizing. After 8 weeks of inulin feeding, CHI mice had increased abundance
of beneficial/anti-inflammatory bacteria, reduced abundance of pathogenic
bacteria, enriched levels of short-chain fatty acids, and restored CBF in both
hippocampi and left thalamus, compared to the CHI-control fed and Sham
groups. Our results indicate that there is an injury- and time-dependent dysbiosis
between CHI and Sham mice; inulin is effective to mitigate dysbiosis and
improve brain injury recovery in the CHI mice. As there are currently no effective
treatments for mTBI, the study may have profound implications for developing
therapeutics or preventive interventions in the future.

3.2

Introduction
Approximately 1.6-3.8 million people sustain a mild traumatic brain

injury (mTBI) in the US annually [139]. This amounts to the hospitalization of
100-300 per 100,000 young adults [139, 140]. The Centers for Disease Control
and Prevention reports that around 5.3 million people live with a permanent
disability after mTBI [141], and there are currently no known restorative therapies
[142].

Reduced cerebral blood flow (CBF) [24, 28] and impaired white
matter integrity (WMI) [143] are typical phenotypes of mTBI. Recent studies
further show that mTBI significantly alters the balance of microbial communities
in the gut of rodents and humans, known as gut dysbiosis [144-146].The effects
of neurotrauma radiate to the intestine and alter the composition and diversity of
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the gut microbiome. This results in reduced levels of putatively beneficial
bacteria which in turn leads to the reduction of short-chain fatty acids (SCFAs),
bacterial metabolites that play a key role in modulating metabolism, vascular
response, and inflammation system-wide [57, 82]. Dysbiosis has been shown to
occur in the acute phase as early as one day post injury in rodent models [145]
and humans [146]. Elucidating that TBI induces dysbiosis pinpoints the gut
microbiome as a potential target to protect against the secondary injury cascade
known to follow TBI [78]. However, gut microbiome composition past the acute
phase of mTBI (1-7 days) has yet to be characterized. This leaves a pivotal gap
in the knowledge pertaining to the long-term changes in gut microbial structure
after the initial injury. Further, it is unknown whether interventions that can
modulate the microbiome, such as diet, could mitigate injury effects in the
chronic phase.

The purpose of the study is two-fold. First, with a longitudinal study
design, we determined the long-term effects of CHI on the gut microbiome, CBF,
and WMI. Second, we determined if prebiotic inulin could mitigate injury-induced
dysbiosis and restore CBF and WMI by modulating gut microbiome from 3
months post injury (mpi) to 5 mpi. We chose inulin because it consists of nondigestible carbohydrates that can stimulate the growth of bacteria that produce
SCFAs [43, 147] and enhance neuroprotection [148, 149]. We expect the
outcomes from the study will advance our knowledge on dysbiosis after CHI from
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acute to chronic phases, and the potential of dietary intervention for facilitating
CHI recovery.

3.3

Methods

3.3.1 Experimental design
We used male C57BL/6 wild-type mice for all experiments (total N
= 20). Ten mice were placed in the Sham group and ten mice were placed in the
closed head injury (CHI) group. Mice were singly housed throughout the study
to avoid feces exchange as mice are coprophagic. Mice were administered a
CHI at 4 months of age. Fig 3-1 shows the study design. Fecal samples were
collected throughout the study at 24 hours before injury, 24 hours post injury, 1.5
mpi, 3 mpi, and 5 mpi. Before diet administration, at 3 mpi we assessed CBF
and WMI (indexed by fractional anisotropy (FA)) using MRI. After this, mice were
fed either a prebiotic diet containing inulin (catalog number 1817795-203) that is
fermentable (Sham-Inulin, CHI-Inulin) or a control diet containing cellulose
(catalog number 1817794 -203) that is nonfermentable (Sham-Control, CHIControl) for a period of 8 weeks, or until 5 mpi (9 months of age) (n = 5/group).
Table 3-1 shows the diet composition. We fed the mice 8% inulin because 8%
inulin has shown positive results on the gut microbiome and related metabolites,
as well as other metrics such as brain and systemic metabolism in previous
studies from our lab [43]. Inulin has a higher percentage of carbohydrates than
cellulose because inulin is a fermentable fiber which means that inulin can be
fermented by the gut microbiome and turned into metabolites such as SCFAs
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which are energy sources to the body [150]. The mice had ad libitum access to
the diets, and we measured the weight of the mice and the weight of the
remaining food biweekly to estimate the food intake during the feeding period. At
3 mpi we assessed CBF and FA prior to diet administration. At 5 mpi we again
used multi-modal MRI metrics to assess CBF and FA. Mice were euthanized by
carbon dioxide inhalation and decapitated. Cecum, blood, and brain tissues were
collected thereafter for metabolomics and other biochemical analyses. All
experimental procedures were performed according to NIH guidelines and
approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Kentucky (UK).

3.3.2 Closed Head Injury

Briefly, as previously described [151, 152], mice were anesthetized
with isoflurane (4-5% induction followed by 2-3% maintenance) prior to insertion
of ear bars to stabilize the head in the digital mouse stereotaxic frame (Stoelting
Co., Chicago, IL). A midline sagittal scalp incision was made and a 1ml latex
bulb (Fisher Scientific) was placed under the head and filled with water to
displace the force during impact from the ears. An electromagnetic impactor was
used to deliver a single controlled mid-line cortical impact at 5.0±0.2 m/s, 100ms
dwell time, and 1.0mm impact depth. Planned exclusion criteria included
depressed skull fracture or bleeding; however, no mice were excluded from the
study. Sham-injured mice underwent identical surgical procedures, but no impact
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was delivered. Righting-reflex was recorded as an acute neurological
assessment. Within one hour after injury, animals were fully conscious and able
to ambulate.

3.3.3 Gut Microbiome Sequencing

Fecal samples were collected by putting each mouse in a clean
autoclaved cage and waiting for it to defecate normally. Samples were collected
during a 2-hour window from 7 am to 9 am. Samples were used to obtain
genomic DNA. QIAGEN DNeasy PowerSoil Kit was used per manufacturers’
guidelines. Shotgun metagenomic sequencing was done by CosmosID. Briefly,
DNA libraries were assembled using the CosmosID proprietary library prep kit
and pooled by adding an equimolar ratio of each sample on a high sensitivity
chip to estimate size. Libraries were then sequenced using an Illumina Miseq
platform. Unassembled reads were directly analyzed by the CosmosID
bioinformatics platform (CosmosID Inc., Rockville, MD), which allows for multikingdom microbiome analysis, profiling of antibiotic resistance and virulence
genes, and quantification of relative abundance. CosmosID uses a highperformance k-mer based algorithm that disambiguates hundreds of millions of
short reads of a sample into the microorganisms that the sequences represent.
Matrix tables of detected taxa were generated, and heat maps were produced.
These allow for visualization of diversity and abundance of each microbial taxa.
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3.3.4 MRI Data acquisition

We used the 7T Clinscan MR scanner (Siemens, Germany) at the
Magnetic Resonance Imaging & Spectroscopy Center of UK. Mice were
anesthetized with 4.0% isoflurane for induction and then maintained in a 1.2%
isoflurane and air mixture using a facemask. Heart rate (90–130 bpm.),
respiration rate (70-90 breaths per minute), and rectal temperature (37 ± 0.5°C)
were monitored. A water bath with circulating water at 45–50°C was used to
maintain the body temperature. Quantitative CBF (with units of mL/g per minute)
was measured using MRI-based pseudo-continuous arterial spin labeling
(pCASL) techniques [153]. Paired images were acquired in an interleaved
fashion with FOV = 18 x 13.5 mm2, matrix = 64 x 48, slice thickness = 1 mm, 6
slices, labeling duration = 200ms, TR = 4,000 ms, TE = 20 ms, and 120
repetitions. pCASL image analysis was employed with in-house written codes in
MATLAB (MathWorks, Natick, MA) to obtain quantitative CBF [154]. CBF maps
were visualized and quantitated using Mango image viewer (UT San Antonio,
TX). Diffusion tensor imaging (DTI) is used to characterize microstructural
changes in the brain [155]. The images are acquired using four-segment, spinecho, echo-planar sequence with the following parameters: field of view = 22 ×
14.3 mm, 160 × 160 matrix, slice thickness = 1 mm, slice numbers = 4,
TR = 1400 ms, TE = 42 ms, 90 degree flip angle, b value = 0 and 800 s/mm2,
diffusion direction = 106, diffusion gradient amplitude (G) = 10 and 190 mT/m,
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gradient duration (Δ) = 18 ms, and averages = 1 [156]. Fractional Anisotropy (FA)
values are analyzed using Mango image viewer for regions of interest.

3.3.5 Short chain fatty acid analysis of plasma and cecal contents

Eight SCFAs from cecum and plasma were analyzed with LCMS/MS by Metabolon Inc. (Morrisville, NC): acetic acid (C2), propionic acid (C3),
isobutyric acid (C4), 2- methylbutyric acid (C5), isovaleric acid (C5), valeric acid
(C5), and caproic acid (C6). Both sets of samples were stable labeled with
internal standards and homogenized in an organic solvent. The samples were
then centrifuged followed by an aliquot of the supernatant used to derivatize to
form SCFA hydrazides. This reaction mixture was subsequently diluted, and an
aliquot was injected into an Agilent 1290/AB Sciex QTrap 5500 LCMS/MS
system.

3.3.6 Data analysis
3.3.7 Microbiome diversity and dissimilarity analyses

Alpha diversity (within sample, Shannon index and Chao 1 Index)
and beta diversity (dissimilarities between samples, Bray-Curtis index) were
performed in order to compare the microbial community as a whole between
different sample groups (i.e. diet, injury). Data analysis and visualizations were
performed by CosmosID (Rockville, MD), with Wilcoxon Rank-Sum and
PERMANOVA tests. Linear Discriminant Analysis Effect Size (LEfSe) differential
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abundance analyses were performed between pairs of cohorts to determine taxa
that are significantly enriched in each cohort.

3.3.8 Machine learning (ML) analysis

To identify the bacterial species that play the pivotal role to
differentiate dysbiosis at different timepoint in each group (i.e. Baseline vs. Acute
in Sham and Acute vs. Mid in CHI), we performed ML analysis to rank the
relative importance of the microbiota. We used the Support Vector Machine
(SVM) algorithm for supervised classification and the SHapley Additive
exPlanations (SHAP) to visualize the SVM prediction results. We applied 3-fold
cross-validation and assess the algorithm’s perfronace with Accuracy, F1 score,
and Area Under the Curve (AUC). For SVM, we used the python function
“sklearn.svm.svc” to implement the SVM with hyperparameters:
C=10, gamma=’auto’, probability=True”. For SHAP, we used the function
“KernelExplainer( )” for the SVM model and adopted “summary_plot” functions to
visualize the SVM model predictions.

3.3.9 Statistical analysis

All statistical analyses were completed using GraphPad Prism 9.0
(GraphPad, San Diego, CA, USA). Two-way ANOVAs were performed for
determination of differences between groups (injury type and diet effects)
followed by post-hoc Welch’s t-tests. Levels of statistical significance were
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reached when p < 0.05. For the microbiome, given the multiple comparisons
inherent in analysis of microbiota, between-group relative differences are
assessed using both p-value and false discovery rate analysis (q-value).

3.4

Results

3.4.1 Gut microbial diversity altered differently between CHI and Sham injuries

Figures 3-2A and 3-2B show the beta diversity at the four
longitudinal timepoints of the Sham and CHI groups, respectively. We found
significant difference within the Sham group between the Baseline and Acute
timepoints (Fig 3-2C) (Sum of Squares = 0.3443181, R2 = 0.2042643, F =
4.620575, p = 0.003), and within the CHI group between the Acute and Mid
timepoints (Fig 3-2D) (Sum of Squares = 0.1867712, R2 = 0.127083, F =
2.620517, p = 0.011).

3.4.2 Bacterial species differentiate dysbiosis under Sham and CHI at different
timepoints

Figure 3-3A shows the top 10 microbiota ranked by ML algorithm
that can separate dysbiosis status at the Baseline from Acute timepoint in the
Sham group. The ML performance was robust with 84.9% accuracy, 84.6% F1
score and 88.9% AUC. Compared to the Baseline, we found that Acute timepoint
had decreases in beneficial bacteria such as Akkermansia muciniphila and
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increases in bacteria such as Firmicutes bacterium ASF500 (Table 2). Similarly,
Figure 3-3B shows the top 10 microbiota ranked by ML algorithm that can
separate dysbiosis status at the Acute from Mid timepoint in the Sham group.
The ML performance was also robust with 75.9% accuracy, 74.7% F1 score and
85.6% AUC. Compared to the Acute phase, we found that the Mid timepoint had
decreases in beneficial bacteria such as Lactobacillus johnsonii, and increases
in species from the Lachnospiraceae family, which is known to be associated
with various disease states, such as Lachnospiraceae bacterium A2, 28-4 and
A4. Table 2 shows the relative abundance of the species in the importance
table for each timepoint, with lower values shaded in gray.

3.4.3 CHI mice show decreased CBF and changes in FA compared to Sham
mice

CBF and FA were measured 3 mpi. CBF was shown to be lower in
the CHI group compared to the Sham group in the left (Fig 3-4A) and right
proximal cortex (Fig 3-4B). There are higher levels of FA in the left (Fig 3-4C)
and right fimbria (Fig 3-4D) compared to the Sham group and lower levels of FA
in the right external capsule (Fig 3-4E) compared to the Sham group. Changes
in FA fit with the literature which indicates that decreased FA is expected after
injury, but FA can also be increased after injury potentially due to compensatory
mechanisms or edema [157].

61

3.4.4 Inulin altered gut microbial diversity in both Sham and CHI mice

After two months of inulin feeding at the chronic phase, we found
that alpha diversity was reduced in both the Sham and CHI groups (p < 0.05)
(Fig 3-5A). Similarly, inulin significantly altered beta diversity in the Sham (Fig 35B) (Sum of Squares = 0.3417861, R2 = 0.2355275, F = 2.464733, p = 0.038)
and CHI groups (Fig 3-5C) (Sum of Squares = 0.4846131, R2 = 0.3702754, F =
4.703967, p = 0.012) using the Bray-Curtis index.

3.4.5 Inulin altered gut microbiome at the phylum level predominately in the CHI
mice

At the phylum level, we found that in the CHI group, inulin
increased Verrucromicrobia (p = 0.0008) (Fig 3-6A), and Actinobacteria (p =
0.0359) (Fig 3-6B) but decreased Firmicutes (p = 0.0102) (Fig 3-6C) compared
to the CHI control mice. Inulin significantly increased Proteobacteria in the Sham
group (p = 0.0178) but not the CHI group (p = 0.0590) (Fig 3-6D). No significant
differences of Bacteroidetes were found between the control and inulin diet in
both CHI and Sham groups (Sham control vs. inulin p = 0.1978; CHI control vs.
inulin p = 0.2691). The distribution of the relative abundance of the five phyla is
shown in Fig 3-6E.
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3.4.6 Inulin increased SCFA-producing bacteria and reduced pathogenic
bacteria in CHI mice

Using LEfSe analysis, we determined taxonomic similarities and
differences between Sham (Fig 3-7A) and CHI mice (Fig 3-7B) at the species
level. The control diet selected for species in the CHI and Sham groups including
the Lachnospiraceae family and Clostridium and Clostridioides genera, as well
as other species such as Dorea sp. 5-2 and Oscillibacter sp. 1-3. However, the
species selected for by inulin differ between the Sham and CHI groups. In the
CHI group, but not the Sham group, inulin promoted several bacteria that have a
positive effect on the gut and produce beneficial metabolites such as SCFAs
including Bifidobacterium species (animalis, AGR1258, pseudolongum) and
Akkermansia muciniphila.

The major changes at the species levels are summarized in Fig 38. Based on the LEfSe analysis, we found that inulin increased putatively
beneficial bacteria (Fig 3-8A) and decreased pathobiont bacteria (Fig 3-8B).
Compared to the control diet, the inulin diet decreased Dorea sp. 5-2 and
Oscillibacter sp. 1-3, which have both been positively correlated with intestinal
permeability [158, 159]; Clostridium clostridioforme, which is associated with
bacteriemia [160]; and Clostridioides difficile, a pathobiont [161]. Inulin also
decreased Lachnospiraceae spp. (including L. bacterium 3-2, L. bacterium A2, L.
bacterium 10-1, L. bacterium 28-4, and L. bacterium COE1) which have been
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implicated in colitis [162] and metabolic disorders [163]. Inulin increased
Bifidobacterium pseudolongum, a SCFA producer, Bifidobacterium animalis and
Bifidobacterium sp. AGR2158, which fits with the literature indicating inulin as a
bifidogenic fiber [47]. It also increased Akkermansia muciniphila, which is also a
SCFA producer [164]. Lactobacillus johnsonii does show a decrease in the CHI
group, but this is likely due to out-competition from Bifidobacterium spp. and A.
muciniphila.

3.4.7 Inulin increased cecal and serum SCFA levels in the CHI and Sham mice

In the cecum SCFA analysis, most notably, the inulin-fed groups
(Sham and CHI) showed significant increases in acetic acid (Sham p < 0.0001;
CHI p = 0.0032) (Fig 3-9A), propionic acid (Sham p=0.0070; CHI p = 0.0024)
(Fig 3-9B), and butyric acid (Sham p = 0.0009; CHI p = 0.0193) (Fig 3-9C)
compared to the control fed groups. In the serum, only acetic acid was found
significantly different between the CHI-control and CHI-inulin mice (p = 0.0385)
(Fig 3-9D).

3.4.8 Inulin restored CBF after CHI

We did not observe injury type- or diet-dependent CBF changes at
5 mpi (injury p = 0.4471, F(1,16) = 0.6076; diet p = 0.1783, F(1,16) = 1.982).
However, with post-hoc analysis, we did find higher CBF in inulin-fed vs. control-
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fed CHI mice in the left thalamus (p = 0.0482) (Fig 3-10A), left hippocampus (p =
0.0292) (Fig 3-10B) and right hippocampus (p = 0.0343) (Fig 3-10C).

3.5

Discussion
To our knowledge, our study is the first to characterize the gut

microbiome in the chronic phase (past one week post CHI) [73, 79]. We further
showed that CBF and WMI of the CHI mice were impacted in the acute phase
but normalized to a level similar to that of the Sham mice in the chronic phase.
We summarized our findings in Fig 3-11. It shows that despite the CHI-induced
dysbiosis, that prebiotic inulin was able to increase the level of beneficial
bacteria, reduce the pathobiont bacteria, and elevate SCFAs in the cecal
contents and plasma. Inulin also restored CBF in both hippocampi and the left
thalamus. Inulin may mitigate long-term effects of mTBI due to positive on the
gut microbiome.

An interesting finding from the study is that the Sham mice also
showed dysbiosis at different timepoint compared with the CHI mice. This is
unexpected based upon data from previous studies [165]. Sham mice showed
dysbiosis at the Baseline-Acute phase, while CHI mice showed dysbiosis at the
Acute-Mid phase. The top three species that classify Baseline vs. Acute
timepoints in the Sham group were decreased Akkermansia muciniphila,
increased Firmicutes ASF500, and decreased Dorea sp. 5-2. Decreased
Akkermansia muciniphila has been observed in patients with ulcerative colitis
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and other metabolic disorders, indicating its potential anti-inflammatory
properties [166]. Increases are seen in Firmicutes ASF500 levels with excess
manganese exposure, which is neurotoxic and can lead to Alzheimer’s and
Parkinson’s Disease [167]. Decreased levels of Dorea sp. 5-2 are beneficial as
this species is associated with intestinal permeability [158], indicating the
possible transient nature of dysbiosis in the Sham group. Although there was
some dysbiosis (increased ASF500, decreased Akkermansia muciniphila), there
was also some recovery (decreased D. sp. 5-2). As for the CHI group, between
the Acute to Mid timepoint, the most important feature was the increased
Lachnospiraceae bacterium A2. The Lachnospiraceae family is associated with
colitis [162] and metabolic disorders, such as Type 2 Diabetes, metabolic
syndrome, and glucose metabolism disorders [163]. Another top feature was
decreased Lactobacillus johnsonii, which has probiotic properties such as
immunomodulation and pathogen inhibition. Therefore, its decrease could be
indicative of a dysbiotic state [168].

With diet, we found significant decreases in alpha diversity in the
inulin-fed mice compared to the control-fed mice, in both Sham and CHI groups.
It is likely due to inulin serving as a dominant energy source and selecting for a
limited number of putatively beneficial bacteria, and an overall reduction in alpha
diversity. This is similar to what we observed in a previous study [43]. At species
level, we observed that inulin decreased putatively harmful bacteria compared to
the mice fed the control diet. Dorea sp. 5-2 and Oscillibacter sp. 1-3 have both
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been shown to be positively correlated with intestinal permeability [158, 159] and
are reduced with inulin supplementation. Inulin also showed decreased
Lachnospiraceae spp. compared to the control diet, which is associated with
various disease states [163]. Along with this, inulin decreased levels of
Clostridioides difficile, a common opportunistic nosocomial infection that blooms
when the gut is in a dysbiotic state, such as after antibiotic administration [161].
We speculate that the dysbiotic state of the gut microbiome following CHI
allowed for C. difficile to bloom, but inulin, which increased bacteria with antipathogenic qualities, such as Bifidobacterium pseudolongum, then decreased its
levels [43].

The putatively beneficial bacteria such as Akkermansia muciniphila
and Bifidobacterium pseudolongum are known to be anti-inflammatory in nature,
as both are producers of SCFAs -- B. pseudolongum produces butyrate while
Akkermansia muciniphila produces acetate -- both of which were increased in
CHI mice fed inulin [57]. Butyrate and other SCFAs may be able to inhibit C.
difficile overgrowth by causing the bacteria to lose viability [169, 170]. As we see
increased SCFAs and decreased C. difficle in inulin-fed mice, this could be a
possible protective mechanism of inulin supplementation from increased C.
difficile levels after injury. It is also known that a low abundance of Akkermansia
muciniphila favors the inflammatory process[164], and we saw a much lower
abundance of this bacteria in the control-fed CHI group compared to the inulinfed CHI group. The increased levels of Akkermansia muciniphila in the inulin
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group is also consistent with the literature in that this species thrives on fiber
[164].

We found decreased white matter integrity (indexed by FA) in the
chronic phase of CHI. FA was lower in the external capsule, which is the route
for cholinergic fibers from the forebrain to the cerebral cortex [171]. Higher FA
values were seen in the fimbria, which is the major output tract of the
hippocampus, where damage can cause difficulty in long term recall [172]. It is
possibly due to a neuroplastic response to injury because compensatory
mechanisms are most active during the acute and subacute periods of injury
[157]. However, these higher values could also be due to axonal swelling and
edema in the brain [157]. Interestingly, at 5 mpi, we did not see the FA difference
between the Sham control vs. CHI control group that we saw at 3 mpi. (see Fig
5), which may indicate a normalization of white matter function. This fits with the
literature that FA typically recovers between the acute and subacute periods of
injury recovery [29].

Similar to the pattern found in FA, we also observed that CBF
decreased at 3 mpi, but normalized at 5 mpi, in the CHI mice compared with the
Sham mice. The decreased CBF was found in the proximal cortex on the right
and left side, which is the area adjacent to the injury. Nonetheless, inulin
supplementation in CHI mice restored CBF to Sham levels in the left side of the
thalamus and the left and right sides of the hippocampus. The thalamus plays an
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important role in relaying sensory and motor signals and regulates
consciousness and alertness. This is consistent with a recent study showing that
supplementation with a diet rich in fruit in vegetables attenuated neuromotor and
sensorimotor functions following TBI [42]. It is also possible that inulin influenced
CBF through increased SCFAs. As shown, there were increases in SCFAs with
inulin supplementation, butyrate and propionate in the cecum and acetate in the
cecum and blood. SCFAs are known to increase tight junction proteins in the gut
and brain which leads to less permeable barriers [57]. A less permeable bloodbrain barrier due to increased tight junction protein expression is protective of
blood flow [86]. The gut microbiome is directly related to this, as Bifidobacterium
pseudolongum is a butyrate producer and Akkermansia muciniphila is an acetate
producer. Both were increased with inulin supplementation [47]. Previous studies
from our lab are indicative of this as well [86]. A ketogenic diet given to young
healthy mice increased CBF compared to the control diet and showed similarities
in the gut microbiome to our study with decreased Clostridium spp. and Dorea
spp. and increased Akkermansia muciniphila [86] . Dorea spp. and Clostridium
spp. are both known to increase intestinal permeability [158, 173] whereas
Akkermansia muciniphila is known to protect the gut barrier and produces
SCFAs which are also protective of the blood brain barrier, and ultimately CBF.
Together, changes in abundance of these three species may facilitate protection
of neurovascular functions and may be indicative of why we saw a restoration of
CBF after CHI.
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This study explores changes in the gut microbiome past the acute
phase of injury and sheds new light onto the chronic phase of injury recovery.
Even when administered three months post injury, inulin’s effects still had a
positive impact on recovery through attenuating harmful effects caused by CHI in
the gut microbiome, systemic metabolism, and brain vascular and structural
function. This is in line with previous findings that protecting brain metabolism is
important to mitigate CNS injury [10, 24, 174, 175]. In the future, we could also
use other MRI neuroimaging methods to determining brain metabolic and
vascular functions that may influenced by inulin, including levels of essential
brain metabolites [131], cerebral metabolic rate of oxygen [176, 177], and
cerebral blood volume [178].

A limitation of the study is that we only used male mice. In future
studies, we will include female mice and further identify the potential sexdifferences in response to the diet. Additionally, the Sham injury causing
transient changes in the gut microbiome indicates the importance of including a
naïve cohort in injury studies that aim to better understand changes in the gut
microbiome.

In summary, we found that CHI induces dysbiosis and alterations in
WMI and CBF through the chronic phase of injury. Additionally, we found that
inulin supplementation exerted a beneficial effect on the gut microbiome which in
turn lead to beneficial influence systemically, most pertinently on SCFAs level in
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the cecal contents and plasma, and CBF in hippocampus and thalamus in mice
with chronic CHI. As there are currently no effective treatments for mTBI, the
study may have profound implication for developing therapeutics or preventive
interventions in the future.
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Table 3-1. Diet composition.
Diet
Protein %
Carbohydrate %
Fat %
Fiber %
Energy (kcal/g)

Prebiotic Diet
18.2
59.1 (w/o inulin)
8.9 from inulin
7.1
8.0 (Inulin)
4.08
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Control Diet
18.2
60.2 (w/o inulin)
7.1
8.0 (Cellulose)
3.78

Table 3-1. Comparison of diet composition of the Prebiotic (inulin) diet and
Control (cellulose) diet.
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Table 3-2. Relative abundance of ranked microbial species.
Sham

Relative Abundance

Species

Baseline Sham

Acute Sham

Akkermansia muciniphila

0.051286

0.009855

Firmicutes bacterium ASF500

0.017068

0.025392

Dorea sp. 5-2

0.046402

0.033166

Anaerotruncus sp. G3(2012)

0.012344

0.023688

Bacteroides sp. 1_1_14

0.04354

0.018108

Clostridales_u_s

0.064976

0.125705

Lachnospiraceae bacterium 3-1

0.019942

0.020895

Erysipelotrichaceae bacterium 6_1_45

0.001124

0.002352

Lachnospiraceae bacterium 28-4

0.009306

0.011209

Lachnospiraceae bacterium COE1

0.013027

0.015841

CHI

Relative Abundance

Species

Acute CHI

Mid CHI

Lachnospiraceae bacterium A2

0.047835

0.115548

Lactobacillus johnsonii

0.062292

0.035032

Lachnospiraceae bacterium 10-1

0.011855

0.009426

Clostridiales_u_s

0.104587

0.07117

Lachnospiraceae bacterium COE1

0.012514

0.009342

Eubacterium sp. 14-2

0.006622

0.004595

Bacteroides sp. 1_1_14

0.022325

0.063441

Lachnospiraceae bacterium 28-4

0.009776

0.007619

Lachnospiraceae bacterium A4

0.166382

0.090773

Enterococcus faecalis

0.023502

0.015995
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Table 3-2. Relative abundance of ranked microbial species. Comparison of
relative abundance from ranked microbial species in Fig 4. Lower values are
shaded in gray.
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Figure 3-1. Study design.
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Figure 3-1. Study design. CHI was administered at 4 months of age. Diet was
started 3 mpi (7 months of age) and fecal samples were taken periodically
throughout the study starting 24 hours prior to injury and ending 5 mpi. CBF and
FA were analyzed at 3 mpi and 5 mpi. Cecal contents and plasma were collected
at time of sacrifice.
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Figure 3-2. Longitudinal analysis of beta diversity.
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Figure 3-2. Longitudinal analysis of beta diversity. (A) Sham Beta diversity
(Bray-Curtis Index) between sample longitudinal analysis. (B) CHI Beta diversity
(Bray-Curtis Index) between sample longitudinal analysis. (C) Beta diversity
showed that in the Sham group, the baseline timepoint significantly differed from
the acute timepoint (Sum of Squares = 0.3443181, R2 = 0.2042643, F =
4.620575, p = 0.003). (D) Beta diversity showed that in the CHI group the acute
timepoint significantly differed from the mid timepoint (Sum of Squares =
0.1867712, R2 = 0.127083, F = 2.620517, p = 0.011).
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Figure 3-3. Importance ranking of microbial species.
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Figure 3-3. Importance ranking of microbial species. (A) SHAP values from
ML analysis indicate the top 10 most important microbiota in distinguishing the
Sham Baseline vs. Acute timepoints (B) SHAP values indicate the top 10
features most important in distinguishing the CHI Acute vs. Mid timepoints.
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Figure 3-4. Cerebral blood flow and fractional anisotropy analysis.
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Figure 3-4. Cerebral blood flow and fractional anisotropy analysis. (A-B)
CHI decreases CBF in the (A) left proximal cortex, (B) right proximal cortex
compared to Sham (C-E) CHI increases FA in the (C) left fimbria and (D) right
fimbria and decreases FA in the (E) right external capsule compared to Sham.
Data are presented as mean  SD. *p < 0.05, ***p < 0.001.
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Figure 3-5. Gut microbiome diversity.
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Figure 3-5. Gut microbiome diversity. (A) Alpha diversity (Shannon index)
within sample analysis shows that inulin decreased alpha diversity in Sham and
CHI, (*p < = 0.05). (B) Beta diversity (Bray-Curtis Index) between sample
analysis showed that Sham inulin fed mice had a significantly different diversity
than Sham control fed mice (Sum of Squares = 0.3417861, R2 = 0.2355275, F =
2.464733, p = 0.038). (C) Beta diversity (Bray-Curtis Index) between sample
analysis showed that CHI inulin fed mice had a significantly different diversity
than CHI control fed mice, (Sum of Squares = 0.4846131, R2 = 0.3702754, F =
4.703967, p = 0.012).
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Figure 3-6. Phyla level analysis of gut microbiome.
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Figure 3-6. Phyla level analysis of gut microbiome. (A-D) Quantitative
analysis of phyla. Inulin showed increases in the CHI group for the phyla (A)
Verrucomicrobia and (B) Actinobacteria and decreases in the CHI group for the
phyla (C) Firmicutes. Inulin showed an increase in the Sham group for the phyla
(D) Proteobacteria. (E) Qualitative analysis of phyla to visualize patterns of
changes. Data are presented as mean  SD. *p < 0.05, ***p < 0.001.
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Figure 3-7. Species-level analysis of the gut microbiome.
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Figure 3-7. Species-level analysis of the gut microbiome. (A) Analysis at the
species level of Sham control versus sham inulin mice. (B) Analysis at the
species level of CHI control versus CHI inulin fed mice. Analysis was conducted
using Linear discriminant analysis Effect size (LEfSe). Control-fed CHI or Sham
mice are shown in peach and inulin-fed CHI or Sham mice are shown in teal.
Bars indicate that a specific species was found to be significantly increased with
the diet specified. All shown are statistically significant (p < = 0.05) (LDA > =
2.0).
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Figure 3-8. Inulin increases beneficial bacteria and decreases pathobiont
bacteria.

90

Figure 3-8. Inulin increases beneficial bacteria and decreases pathobiont
bacteria. (A) Inulin increases beneficial bacteria Bifidobacterium spp,
Lactobacillus johnsonii and Akkermansia muciniphila. (B) Inulin decreases
pathobiont bacteria Dorea sp. 5-2, Clostridium clostridioforme, Clostridioides
difficile, Oscillibacter sp. 1-3, and Lachnospiraceae spp. Significant bacteria were
chosen from the LEfSe analysis (p < = 0.05).
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Figure 3-9. Short Chain Fatty Acids (SCFAs) were increased with inulin.

92

Figure 3-9. Short Chain Fatty Acids (SCFAs) were increased with inulin.
Cecal levels SCFAs were increased in sham and CHI groups with inulin including
(A) acetic acid, (B) propionic acid, and (C) butyric acid. Serum levels of (D)
acetic acid were also increased with inulin. Data are presented as mean  SD. *p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 3-10. Inulin increases cerebral blood flow after CHI.
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Figure 3-10. Inulin increases cerebral blood flow after CHI. (A-C) Inulin
increased CBF in the (A) left thalamus, (B) left hippocampus, (C) right
hippocampus compared to controls. Data are presented as mean  SD. *p <
0.05.
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Figure 3-11. Summary of findings
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Figure 3-11. Summary of findings. CHI induced gut dysbiosis and disrupted
cerebral blood flow and brain structural metrics. With prebiotic inulin
supplementation at 3 mpi, results show an increase of putatively beneficial
bacteria and a decrease of pathobiont bacteria, an increase in SCFAs and
restored CBF.
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CHAPTER 4. INULIN SUPPLEMENTATION PRIOR TO MILD TRAUMATIC
BRAIN INJURY IMPROVES OUTCOMES VIA THE GUT-BRAIN AXIS
4.1

Abstract
It has been established that mild traumatic brain injury (mTBI)

negatively alters bacterial diversity and composition within the gut, known as
dysbiosis, in rodents and humans. These changes cause secondary
consequences systemically and, in the brain, through decreased bacterial
metabolites such as short chain fatty acids which play a role in inflammation and
metabolism, as well as reductions in cerebral blood flow and white matter
integrity. These impacts to the gut-brain axis may prolong brain inflammation and
cause long-term consequences for those with a mTBI. Due to this, the gut-brain
axis has become an emerging target for mTBI research. Inulin, a prebiotic fiber,
known to stimulate beneficial bacterial growth in the gut has shown promise in
mitigating symptoms when administered during the chronic period of mTBI
recovery in mice. However, it is unknown whether supplementing inulin before a
mTBI would provide these same benefits to the gut and brain. To fill this gap, we
investigated how mTBI impacts the gut microbiome in comparison to Sham and
Naïve groups at various timepoints post-injury in mice. Finally, we examined if
the modulation of the gut microbiome via inulin supplementation pre-closed head
injury (CHI) would decrease gut dysbiosis and improve neurovascular and
structural integrity. We found that inulin supplementation decreased pathobiont
bacteria, increased beneficial bacteria and significantly altered beta diversity as
early as 24 hours post injury, up to 3 months post injury compared to control fed
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mice. Inulin also increased white matter integrity (indexed by fractional
anisotropy) at 1.5 months and 3 months post injury. Additionally, inulin increased
CBF at 3 months post injury in CHI mice, suggesting neuroprotective benefits.
As there is a lack in preventative solutions for mTBI, this study may be vital in
creating cost-effective, accessible interventions for those who are at risk for
sustaining a head injury.

4.2

Introduction
The magnitude of mild traumatic brain injury (mTBI) continues to

increase with recent estimates suggesting that 42 million people sustain mild
head injuries worldwide every year [179]. It has been coined the “signature
injury” of Iraq and Afghanistan conflicts [19] and an approximated 1.6 million
sport-related concussions occur in the US annually, 50% of which go unreported
[20, 21]. mTBI often has long lasting effects resulting in chronic disabilities [180],
with the CDC reporting that around 5.3 million people live with a permanent
disability after injury [141]. Although there is such a high incidence of this injury
and its long-term effects, efficacious treatments are lacking [142].

The gut-brain axis has emerged as a topic of interest in mTBI
research. There is considerable evidence that demonstrates mild closed head
injury (CHI) in mice can cause intestinal permeability and gut dysbiosis as early
as 24 hours post injury which persists for as long as 3 months post injury [73,
181] by disrupting diversity, increasing pathobiont bacteria and decreasing
99

putatively beneficial bacteria [73, 79]. CHI also has a role in reducing multifaceted bacterial metabolites such as short chain fatty acids (SCFA) that
modulate metabolism, inflammation and vascular response system wide.
Together, these changes cause a systemic response that perpetuates long-term
secondary sequalae and disability [78]. Included in this long-term systemic
response is a reduction of cerebral blood flow (CBF) [24, 28] and changes in
white matter integrity (WMI) [143] which are typical chronic phenotypes of
traumatic brain injury.

Current literature, as well as a recent study from our lab, suggest
that manipulation of the gut microbiome through dietary intervention may be
actionable to reduce long term symptoms after mTBI [42]. Our lab recently
showed that when prebiotic inulin (a dietary fiber) was administered during the
chronic phase of injury recovery, it was able to increase the level of beneficial
bacteria, reduce pathobiont bacteria, and elevate SCFAs in the cecal contents
and plasma. Inulin also restored CBF in both hippocampi and the left thalamus.
In another recent study, young male mice were given a moderate TBI, and those
fed prior to the injury with various supplements of fruit or vegetable blends had
reduced neuroinflammation and improved functional recovery compared to those
fed a control diet [42, 181]. However, as our study administered treatment during
the chronic phase of injury and the aforementioned study does not investigate
the gut microbiome, it remains unknown if prophylactic dietary intervention
targeting the gut microbiome will have the same protective effects after injury.
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The goal of the study is to determine if prophylactic dietary
modulation of the gut microbiome can increase the presence of beneficial
bacteria, decrease pathobiont bacteria and protect brain vascular, structural and
systemic metabolic functions after mTBI. To examine the impact of prophylactic
dietary intervention, we will use the prebiotic fiber, inulin, a non-digestible
carbohydrate fermented in the gastrointestinal tract, known from our previous
work to exert positive effects when administered during the chronic phase of
mTBI. The central hypothesis is that prophylactic feeding of inulin prior to injury
is protective of dysbiosis, systemic metabolism and brain vascular and structural
integrity.

4.3

Methods

4.3.1 Experimental design

We used male C57BL/6 wild-type mice for all experiments (total N
= 71). The mice were split into two cohorts with a total six experimental groups.
Mice were singly housed throughout the study to avoid feces exchange as mice
are coprophagic. Diet administration started at 2 months of age (2 months prior
to injury) and mice were administered a CHI at 4 months of age. Figure 4-1
shows the study design. Fecal samples were collected throughout the study at 2
months of age (prior to diet administration), 24 hours before injury, 24 hours post
injury, 1.5 months post injury and 3 months post injury. At 2 months of age (2
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months prior to injury) mice started either a prebiotic diet containing inulin
(catalog number 1817795-203) that is fermentable (Naïve-Inulin n = 12, ShamInulin n = 12, CHI-Inulin n = 12) or a control diet containing cellulose (catalog
number 1817794 -203) that is nonfermentable (Naïve-Control n =11, ShamControl n = 12, CHI-Control n = 12) for a period of 8 weeks, or until 3 mpi (7
months of age). Table 4-1 shows the diet composition. We fed the mice 8%
inulin because 8% inulin has shown positive results on the gut microbiome and
related metabolites, as well as other metrics such as brain and systemic
metabolism in previous studies from our lab [43]. Inulin has a higher percentage
of carbohydrates than cellulose because inulin is a fermentable fiber. This
means that inulin can be fermented by the gut microbiome and turned into
metabolites such as SCFAs, which are energy sources to the body [150]. Mice
had ad libitum access to the diets, and we measured the weight of the mice and
the weight of the remaining food biweekly to estimate the food intake during the
feeding period. At 1.5 mpi we assessed WMI (indexed by fractional anisotropy
(FA)). At 3 mpi we assessed WMI and cerebral blood flow (CBF) using MRI. The
mice also underwent the active avoidance behavioral test at this time. Active
avoidance methods and data can be found in the supplementary materials. Mice
were euthanized by carbon dioxide inhalation and decapitated. Cecal contents
was collected thereafter for short chain fatty acid analyses. All experimental
procedures were performed according to NIH guidelines and approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of
Kentucky (UK).
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4.3.2 Closed head injury

Briefly, as previously described [151, 152], mice were anesthetized with
isoflurane (4-5% induction followed by 2-3% maintenance) prior to insertion of
ear bars to stabilize the head in the digital mouse stereotaxic frame (Stoelting
Co., Chicago, IL). A midline sagittal scalp incision was made and a 1ml latex bulb
(Fisher Scientific) was placed under the head and filled with water to displace the
force during impact from the ears. An electromagnetic impactor was used to
deliver a single controlled mid-line cortical impact at 5.0±0.2 m/s, 100ms dwell
time, and 1.0mm impact depth. Planned exclusion criteria included depressed
skull fracture or bleeding; however, no mice were excluded from the study.
Sham-injured mice underwent identical surgical procedures, but no impact was
delivered. Naïve mice did not undergo any surgical procedures or anesthetic
administration. Righting-reflex was recorded as an acute neurological
assessment. Within one hour after injury, animals were fully conscious and able
to ambulate.

4.3.3 Gut microbiome sequencing and analysis

Fecal samples were be collected in a two-hour window between 7-9am.
Samples were frozen at -80 degrees until DNA extraction. Genomic DNA was
extracted from fecal samples and ZymoBIOMICS™ DNA Mini Kit per
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manufacturers guidelines. PCR amplification and library pooling was performed
at the DNA Services (DNAS) facility, Research Resources Center (RRC),
University of Illinois at Chicago (UIC). Sequencing was performed at the W.M.
Keck Center for Comparative and Functional Genomics at the University of
Illinois at Urbana-Champaign (UIUC).

Forward and reverse reads were merged using PEAR [107]. Primer
sequences were identified using Smith-Watermann alignment and trimmed from
the sequence. Reads that lacked either primer sequence were discarded.
Sequences were then trimmed based on quality scores using a modified Mott
algorithm with PHRED quality threshold of p = 0.01, and sequences shorter than
300 bases after trimming were discarded. QIIME v1.8 was used to generate OTU
tables and taxonomic summaries [108]. Briefly, the resulting sequence files were
merged with sample information. Operational taxonomic unit (OTU) clusters were
generated in a de novo manner using the UCLUST algorithm with a 97%
similarity threshold [182]. Chimeric sequences were identified using the
USEARCH61 algorithm with the GreenGenes 13_8 reference sequences [183].
Taxonomic annotations for each OTU were using the UCLUST algorithm and
GreenGenes 13_8 reference with a minimum similarity threshold of 90% [182,
183]. Taxonomic and OTU abundance data were merged into a single OTU table
and summaries of absolute abundances of taxa were generated for all phyla,
classes, orders, families, genera, and species present in the dataset. The

104

taxonomic summary tables were then rarefied to a depth of 10,000 counts per
sample.

4.3.4 Diversity and dissimilarity analyses

Shannon and Bray-Curtis indices were calculated with default parameters
in R using the vegan library [109, 184]. The rarefied species data, taxonomic
level 7, were used to calculate both indices. Plots were generated in R using the
ggplot2 library [185]. Significant difference among tested groups was determined
using the Kruskal-Wallis one-way analysis of variance. The group significance
tests were performed on the rarefied species data, taxonomic level 8 (species),
using the group_significance.py script within the QIIME v1.8 package.

4.3.5 MRI data acquisition

We used the 7T Bruker BioSpin MRI GmbH Scanner (Siemens, Germany)
at the Magnetic Resonance Imaging & Spectroscopy Center of UK. Mice were
anesthetized with 4.0% isoflurane for induction and then maintained in a 1.2%
isoflurane and air mixture using a facemask. Heart rate (90–130 bpm.),
respiration rate (70-90 breaths per minute), and rectal temperature (37 ± 0.5°C)
were monitored. A water bath with circulating water at 45–50°C was used to
maintain the body temperature. Qualitative CBF was measured using a Perfusion
Fair Rare perfusion weighted sequence in an interleaved fashion (TI loop
outside) with the following parameters: FOV = 20 x 20 mm2, matrix = 128 x 112,
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slice thickness = 1 mm, 1 slice, TR = 10000 ms, TE = 44 ms, echo spacing = 5.5
ms, rare factor = 16, resolution = 0.156 x 0.179, anti-aliasing = 1 x 1, excitation
angle = 90 degrees, refocusing angle = 180 degrees, 8 repetitions, TI values =
20 ms with constant recovery; calculated inversion pulse with 4 mm inversion
slab thickness and 1.5 mm slice package margin. CBF was visualized and
quantitated using Mango image viewer (UT San Antonio, TX). Diffusion tensor
imaging (DTI) is used to characterize microstructural changes in the brain [155].
The images are acquired using the Bruker DTI:EPI, SpinEcho sequence with the
following parameters: TE = 0.512 ms, TR = 2000 ms, diffusion time = 8.4 ms,
encoding direction 2.5 ms. A DTI diffusion scheme was used with a total of 40
sampling direction acquired, b-value = 672.39 s/mm2, in plane resolution =
0.179688 mm, slice thickness 0.8 mm. Tensor metrics were calculated using
DWI with b-value lower than 1750 s/mm2. Fractional Anisotropy (FA) values were
analyzed using DSI studio [186]

4.3.6 Short chain fatty acids of cecal contents

Samples were prepared for LCMS by adding 200 uL of isopropyl
alcohol to 20 mg of cecal contents in a 1.5 ml microcentrifuge tube to reach a
mass to volume ratio of 0.1 mg/uL. Samples were shaken for 30 min and then
centrifuged for 30 min at 13,000xg. 50 ul of the supernatant was transferred to a
glass vial and derivatization reagent solutions were added. Derivatization was
performed in an incubator at 37 degrees Celsius for 45 minutes. Standards
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(acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric
acid and 2-methylbutanoic acid at 4 ul/mL) wer also derivatized in the same
manner as a positive control. The solution was then directly injected into the
LCMS. Chromatographic separation was achieved on C18 2.7 um x 150 mm
using mobile phase (A) water +0.1% formic acid and (B) acetonitrile

4.3.7 Statistical analysis

All statistical analyses were completed using GraphPad Prism 9.0
(GraphPad, San Diego, CA, USA). Two-way ANOVAs were performed for
determination of differences between groups. Based on the a-priori hypothesis
constructed from our pilot study data, we expected a specific pattern of
responses, leading us to plan a set of pairwise comparisons (Naïve control vs.
Sham control, Naïve control vs. CHI control, Sham control vs. CHI control (to
assess injury effects), Naïve control vs. Inulin, Sham control vs. Inulin, CHI
control vs inulin (to assess dietary effects)). As these comparisons were
determined as part of the experimental design, they qualify as planned
comparisons. These planned comparisons will be reported in addition to ANOVA
results [187-189]. Planned comparisons were carried out using Welch’s t-test.
Levels of statistical significance were reached when p < 0.05. For the
microbiome, given the multiple comparisons inherent in analysis, between-group
relative differences are assessed using both p-value and false discovery rate
analysis (q-value).
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4.4

Results: Injury Effects

4.4.1 Alpha and beta diversity are affected 24 hours post injury

An overall injury effect (F(2,67), = 3.6375, p =0.0319) indicated
there were significant differences in Shannon index alpha diversity (within
sample analysis) between the Naïve control and Sham control mice 24 post
injury (Fig 4-2A). Pairwise comparisons showed significantly lower alpha
diversity in the Sham group compared to Naïve (p = 0.044). Bray-Curtis beta
diversity (between sample analysis) (Fig 4-2B) showed a significant effect due to
injury (Sum of Squares = 0.146183, R2 = 0.133, F = 6.80864, p = 0.001).
Pairwise analysis indicated differences between Naïve control vs. Sham control
(p = 0.001) and Naïve control vs. CHI control (p = 0.001). This is consistent with
previous data where alpha diversity is affected acutely in the Sham group after
injury, whereas beta diversity is affected in both groups [181].

4.4.2 Injury alters the gut microbiome at the phyla level in Sham and CHI mice
24 hours post injury and 1.5 months post injury

At 24 hours post injury (Fig 4-3A) higher levels in Sham and CHI
mice compared to naïve mice are seen in Verrucomicrobia (Sham vs. Naïve Q =
1.65e-03, CHI vs. Naïve Q = 7.78e-03), and Bacteroidetes (Sham vs. Naïve Q =
3.71e-06, CHI vs. Naïve Q = 8.07e-04). Higher levels of Proteobacteria (Sham
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vs. Naïve Q = 1.21e-02) are only seen in the Sham group compared to the
Naïve.

By 1.5 months post injury (Fig 4-3B), Sham mice show higher
levels of Bacteroides compared to CHI and Naïve (Sham vs. Naïve Q = 0.04,
Sham vs. CHI = 0.05). This is indicative of Sham microbiome recovering from a
dysbiotic state as commensal Bacteroides species are increasing, such as B.
ovatus and B. thetaiotaomicron.

4.4.3 Pathobiont bacteria are seen at higher levels in Sham and CHI mice 24
hours and 1.5 months post injury compared to Naïve mice

Compared to the Naïve control group, Sham and CHI mice show
increased pathogenic bacteria at 24 hours post injury (Fig 4-4A) including
Shigella spp , Escherichia spp, (both part of the Proteobacteria phylum)
Akkermansia muciniphila (part of the Verrucomicrobia phylum) and
Parabacteriodes distasonis (part of the Bacteroidetes phylum) which are all
known to be pathobiont bacteria: Sham (S. dysenteriae Q = 2.23e-04, S. flexneri
Q = 1.64e-04, S. boydii Q = 1.35e-05, E. coli Q = 5.03e-07, Escherichia other Q
= 3.00e-06, A. muciniphila Q = 0.02), and CHI (S. dysenteriae Q = 2.92e-05, S.
flexneri Q = 0.01, S. boydii Q = 5.82e-05, E. coli Q = 1.12e-05, Escherichia other
Q = 4.53e-05, A. muciniphila Q = 0.05, P. distasonis Q = 6.10e-03). Although
both Sham and CHI show increased pathobiont bacteria 24 hours post injury, the
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magnitude of dysbiosis is much higher in the Sham group with a higher presence
of E. coli, A. muciniphila and Shigella spp reflected in the counts per million.

At 1.5 months post injury (Fig 4-4B), the bloom of E. coli and
Shigella spp has dissipated but pathobiont bacteria are still present in the sham
control group (Turicibacteraceae; Other;Other Q = 0.03, E. coli Q = 0.05) and
CHI control group (Turicibacteraceae; Other;Other Q = 0.03) compared to the
naïve control mice. Whereas overall levels pathobiont bacteria in Sham mice
have decreased from 24 hours to 1.5 months post injury, in the CHI group the
level seems to stay consistent apart from A. muciniphila.

4.4.4 Sham mice exhibit a more balanced microbiome 1.5 months post injury
that is not present in CHI mice

Sham mice exhibit a more transiently dysbiotic microbiome than
CHI mice. By 1.5 months post injury (Fig 4-5), dysbiosis seems to be recovering
in Sham mice with increased levels of beneficial bacteria which is not seen in
CHI mice (B. other (Q = 4.55e-04), B. pseudolongum (Q = 3.14e-03), B. ovatus
(Q = 1.55e-03) and B. thetaiotaomicron (Q = 1.27e-03)). This is similar to what
we saw in our pilot study, where Sham mice show higher dysbiosis at 24 hours
post injury than the CHI, but Sham mice show a more balanced microbiome by
1.5 months post injury.
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4.4.5 Cerebral blood flow is affected in control fed CHI mice 3 months post
injury

Compared to Naïve mice, CHI mice exhibit decreased CBF 3
months post injury in the (Fig 4-6A) left proximal cortex (p = 0.0231), (Fig 4-6B)
right hippocampus (p = 0.0496), (Fig 46-C) left thalamus (p = 0.0449) and (Fig
4-6D) right thalamus (p = 0.0324).

4.5

Results: Diet affects

4.5.1 Beta diversity is more effected by diet than alpha diversity

Alpha diversity (Shannon index, within sample analysis) was not
affected by diet 24 hours post injury (Fig 4-7A). By 1.5 months post injury (Fig 47B) alpha diversity is affected by diet (F(1,66) = 4.437, p = 0.0391) with pairwise
comparisons showing Naïve inulin mice had lower alpha diversity than Naïve
control mice (p = 0.013) as did CHI inulin mice compared to CHI control mice (p
= 0.033). This is consistent with previous work from our lab whereas reduced
diversity is likely due to a reduction of pathogenic bacteria [43]. By 3 months post
injury, alpha diversity no longer shows any differences (Fig 4-7C).

Beta diversity (Bray-Curtis index, between sample analysis)
shows and overall effect due to diet at 24 hours post injury (Fig 4-7D) (Sum of
Squares = 0.213789, R2 = 0.194, F = 19.9148, p = 0.001) with pairwise
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comparisons showing significant differences between Naïve control and Naïve
inulin mice (p = 0.001), Sham control and Sham inulin mice (p = 0.001) and CHI
control and CHI inulin mice (p = 0.001). At 1.5 months post injury (Fig 4-7E),
there is again an overall effect due to diet (Sum of Squares = 0.34854, R2 =
0.331, F = 34.352, p = 0.001) with all three groups exhibiting significant
differences between control and inulin groups (Naïve p = 0.001, Sham p = 0.001,
CHI p = 0.001). By 3 months post injury (Fig 4-7F), beta diversity continues to
show an overall effect due to diet (Sum of Squares = 0.30966, R2 = 0.386, F =
41.1556, p = 0.001) with pairwise analyses again indicating significant
differences between control fed and inulin fed mice in all three groups (Naïve p =
0.001, Sham p = 0.001, CHI p = 0.001).

4.5.2 Phyla that encompass beneficial bacterial species are increased with
inulin supplementation

At 24 hours post injury (Fig 4-8A), compared to the control fed
mice, inulin fed mice show an increased level of Actinobacteria (Naïve control vs.
Inulin Q = 3.86e-04, Sham control vs. Inulin Q = 3.58e-03, CHI control vs. inulin
Q = 1.56e-08) and Firmicutes (Naïve control vs. Inulin Q = 1.44e-06, Sham
control vs. Inulin Q = 1.16e-08, CHI control vs. inulin Q = 1.06e-09), generally
coming from beneficial bacteria such as Bifidobacterium spp and Lactobacillus
spp.
At 1.5 months post injury (Fig 4-8B), the same pattern is seen,
with higher levels of Actinobacteria (Naïve control vs. Inulin Q = 1.19e-04, Sham
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control vs. Inulin Q = 4.40e-05, CHI control vs. inulin Q = 2.44e-07) and
Firmicutes seen in inulin fed mice compared to control fed mice (Naïve control
vs. Inulin Q = 6.29e-08, Sham control vs. Inulin Q = 1.07e-08, CHI control vs.
inulin Q = 3.35e-04).

At 3 months post injury (Fig 4-8C) only Firmicutes are seen in
higher levels in inulin fed mice than control fed mice (Naïve control vs. Inulin Q =
9.88e-06, Sham control vs. Inulin Q = 5.32e-13, CHI control vs. inulin Q = 4.84e03).

4.5.3 Pathobiont bacteria peak at different timepoints in Sham and CHI control
fed mice

At 24 hours post injury (Fig 4-9A), Escherichia coli and Shigella
spp are significantly increased in Sham control fed mice (E. coli Q = 4.15e-08, S.
dysenteriae Q = 2.14e-04, S. flexerni Q = 2.66e-05, S. boydii Q = 2.91e-06) and
CHI control fed mice (E. coli, Q = 1.86e-08, S. dysenteriae Q = 1.39e-04, S.
flexerni Q = 0.04 , S. boydii Q = 2.02e-05) compared to inulin fed mice. Although
both groups do show significant increases, it is clear that the magnitude of
increase is much larger in the Sham mice than CHI mice, showing that dysbiosis
is peaking at 24 hours post injury in Sham control fed mice.

By 1.5 months post injury (Fig 4-9B), pathobiont bacteria are
decreased in sham control mice compared to inulin mice when comparing to 24
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hours post injury. However, there are still some differences in Desulfovibrio spp
and Lachnospiraceae bacterium 28-4 (L bacterium 28-4 Q = 9.01e-08, D. other
Q = 0.02). As for the CHI group at 1.5 months post injury, it seems dysbiosis
stays at a consistent level compared to 24 hours post injury with increased levels
of various pathobiont bacterial species including Desulfovibrio spp and known
pathogen Pseudomonas aeruginosa (L bacterium 28-4 Q = 6.33E-19, D. piger Q
= 5.01e-03, D. other Q = 0.01, P. aeurgenosa Q = 0.02). Sham mice showing a
recovery of dysbiosis by 1.5 months post injury is consistent with our previous
study which showed sham mice to have more transient dysbiosis than CHI mice
[181].

By 3 months post injury (Fig 4-9C), there are some
pathobiont bacteria still present in Sham mice but there is a more complete
recovery from the dysbiotic state seen 24 hours post injury (L. bacterium 28-4 Q
= 7.55E-10). CHI control fed mice exhibit a peak in dysbiosis 3 months post
injury with higher levels of known pathogenic bacteria such as E. coli spp,
Streptococcus spp, Shigella spp, and P. aeruginosa which are not seen in sham
mice (L. bacterium 28-4 Q = 3.26E-17, S. pyogenes Q = 5.45e-05, D. piger Q =
4.42e-04, D. other Q = 0.03, E. coli Q = 1.79e-03, S. dysenteriae Q = 0.04, S.
other Q = 2.14e-12, S. boydii Q = 0.02, P. aeurogenosa Q = 1.67e-05). This is
also consistent with our previous study showing CHI mice have a peak of
dysbiosis 1.5 months to 3 months post injury, a much longer and more drawn out
dysbiotic state than Sham mice [181].
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4.5.4 Beneficial bacteria are present in inulin fed mice as early as 24 hours post
injury, and persist until 3 months post injury

At 24 hours post injury (Fig 4-10A) inulin fed mice show higher
levels than control fed mice of Bifidobacterium spp in Naïve (B. other Q = 4.19e04), Sham (B. other Q = 2.89e-06, B. pseudolongum Q = 3.48e-04) and CHI (B.
other Q = 1.63E-23, B. pseudolongum Q = 1.34E-34) and higher levels of
Lactobacillus spp in CHI mice (L. gasseri Q = 5.14e-03).

At 1.5 months post injury (Fig 4-10B) inulin fed mice show higher
levels than control fed mice (similar to that of 24 hours post injury) of
Bifidobacterium spp in Naïve (B. other Q = 1.35e-05, B animalis Q = 1.75e-04
and B. pseudolongum Q = 1.37e-03), Sham (B. other Q = 3.98e-08 , B animalis
Q = 2.53e-07 and B. pseudolongum Q = 8.97e-06, B. bifidum Q = 1.93e-04) and
CHI (B. other Q = 2.93E-43 , B animalis Q = 2.43E-25 and B. pseudolongum Q =
1.40E-26) and higher levels of Lactobacillus spp. in Sham (L. gasseri Q = 0.01,
L. johnsonii Q = 0.03) and CHI (L. gasseri Q = 7.53e-05, L. johnsonii Q = 1.21e06).

At 3 months post injury (Fig 4-10C) inulin fed mice continue to
show higher levels than control fed mice of Bifidobacterium spp. in Naïve (B.
other Q = 4.52e-05, B. animals, Q = 7.18e-05, B. pseudolongum Q = 4.74e-03),
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Sham (B. other Q = 1.46e-05 , B animalis Q = 2.23e-04, B. pseudolongum Q =
6.07e-04, B. bifidum Q = 2.46e-03) and CHI (B. other Q = 1.46e-06, B animalis
Q = 2.24e-06, B. pseudolongum Q = 3.38e-05, B. bifidum Q = 6.75e-03) and
higher levels of Lactobacillus spp in Sham (L. johnsonii Q = 0.03) and CHI (L.
gasseri Q = 3.75e-03).

There are no differences in levels of beneficial bacteria between
Naïve, Sham and CHI inulin fed mice at 24 hours, 1.5 months or 3 months post
injury. This could be indicative of inulin protecting against dysbiosis, even during
its peak in the Sham group at 24 hours post injury and the CHI group at 3
months post injury.

4.5.5 Short chain fatty acids levels are altered by inulin

All three SCFAs showed a significant effect due to diet at three
months post injury. There are decreased levels of acetate (Fig 4-11A) in inulin
fed mice compared to control fed mice in the Naïve (p =0.0052) and Sham mice
(p = 0.0118). As we expect SCFAs to increase with inulin, this was unexpected.
There are multiple reasons this could be occurring, including higher levels of
acetate producing bacteria in control fed animals.

As expected, we see higher levels of butyrate (Fig 4-11B) in inulin
fed Naïve (p < 0.0001), Sham (p < 0.0001) and CHI (p = 0.0001) mice compared
to controls, as well as higher levels of propionate (Fig 4-11C) in inulin fed Sham
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(p = 0.0432) and CHI (p = 0.0482) mice compared to controls. This is consistent
with our previous findings [181].

4.5.6 Inulin increased fractional anisotropy 1.5 months post injury

The left corpus callosum (Fig 4-12A) showed a significant overall
effect due to diet (F(1,29) = 4.416, p = 0.044). Although pairwise comparisons
did not show any significant differences there is a clear trend of inulin fed mice
exhibiting higher levels of FA compared to control fed mice. The left external
capsule (Fig 4-12B) also shows a significant overall effect due to diet (F(1,29) =
4.210, p = 0.0493), with pairwise comparisons showing increased FA in naïve
inulin fed mice compared to control fed mice (p = 0.0326).

4.5.7 Inulin increased Fractional Anisotropy 3 months post injury

The right corpus callosum (Fig 4-13A) showed a significant effect
due to diet (F(1,57) = 4.69, p = 0.0345). Pairwise comparisons indicated higher
FA in sham inulin fed mice compared to control fed mice (p = 0.0461). The right
internal capsule (Fig 4-13B) showed a significant effect due to diet (F(1,57) =
5.125, p = 0.0274) with pairwise comparisons indicating higher FA in CHI inulin
fed mice compared to control fed mice (p = 0.0317). In the left external capsule
(Fig 4-13C) pairwise comparisons indicated higher FA in sham inulin fed mice
compared to control fed mice (p = 0.0228). Although in our previous study we
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didn’t see increased FA due to inulin supplementation, this could have been due
to lack of power, which was taken into account in the present study [181].

4.5.8 Inulin increased cerebral blood flow 3 months post injury in CHI mice

Pairwise comparisons in the right hippocampus showed a
significant increase in CBF in the CHI inulin group compared to the CHI control
group in the right hippocampus (p = 0.0309) (Fig 4-14). This is consistent with
our previous study that showed inulin increased CBF even when administered
during the chronic period of recovery of CHI [181].

4.6

Discussion
In this study, we show that the prebiotic inulin exerts positive

effects systemically when administered prophylactically to mice that undergo
CHI. CHI control fed mice show a disrupted gut microbiome with increased levels
of pathobiont bacteria, altered diversity and decreased cerebral blood flow 3
months post injury, in comparison to naïve control fed mice. Inulin beneficially
alters the diversity and composition of the naïve, Sham and CHI mice by
increasing beneficial bacterial species throughout the study. Inulin also mitigates
the increased levels of pathobiont bacteria seen in control fed mice. Additionally,
inulin increases the levels of beneficial metabolites such as short chain fatty
acids. In the brain, inulin exerts beneficial effects seen through increased levels
of fractional anisotropy 1.5- and 3-months post injury, as well as increased CBF
in CHI mice 3 months post injury. Taken together, these results show that inulin
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supplementation before injury mitigates CHI induced dysbiosis, alterations in
metabolism and detrimental changes in CBF and white matter integrity.

In alignment with our previous study, sham and CHI mice show
peak dysbiosis at different timepoints. Sham mice show a transient dysbiotic
state that peaks at 24 hours post injury and recovers by 1.5 months post injury.
A recent study showed that mice exposed to isoflurane for 4 hours showed
decreased alpha diversity and a change in microbial composition after exposure
[190]. Although our mice are under anesthetic for a much shorter time this
distinctly different patterns of dysbiosis in Sham and CHI mice has now been
replicated in two of our studies. This pattern may be attributed to anesthetic
exposure. Whereas Sham mice are only exposed to isoflurane and not injured, it
is possible that the anesthetic is the major contributor to the dysbiotic state
exhibited by these mice. However, in CHI mice, the pattern may differ due to a
combined effect of anesthetic and injury. CHI mice show a consistent dysbiotic
state starting at 24 hours post injury that gradually increases to its peak at 3
months post injury. It is possible that early dysbiosis (24 hours post injury) is due
mostly to isoflurane. However, the dysbiotic state increasing overtime (1.5 to 3
months post injury) can be attributed to injury, as this effect is not seen in Sham
mice. This again highlights the importance of using naïve mice in microbiome
studies, as they are not exposed to any anesthetic.
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We believe this also brings attention to the need for CHI studies
that include the gut microbiome to be carried out into the chronic period of
recovery. Most studies do not look at the gut microbiome past the acute phase of
recovery, or 1 week post injury [73, 79]. As we found CHI mice show their peak
dysbiotic state between 1.5- and 3-months post injury, it provides evidence that
only looking at the response of the gut microbiome up to 7 days post injury does
not give the full picture of the effects of CHI.

To better understand the effects of injury, we assessed how Sham
and CHI control fed mice responses differed from Naïve control fed mice. Sham
and CHI control fed mice both saw increased levels of the phyla Verrucomicrobia
which consists of species such as Akkermansia muciniphila. A. muciniphila
shows an increase at 24 hours post injury in Sham and CHI control fed mice
compared to Naïve mice. Although A. muciniphila is mostly seen as a probiotic
species, in environments of low fiber it can bloom by feeding on the mucus layer
of the gut as an alternative energy source [164]. This causes a degradation of
the mucosal layer, leading to intestinal permeability and promotes pathogen
susceptibility [164]. This could explain why we see higher levels of pathogenic
bacteria such as Shigella spp and E. coli in Sham and CHI mice 24 hours post
injury. E. coli is an opportunistic pathogen, and Shigella is a highly virulent
pathogen, and a pathovar of E. coli [191, 192]. Shigella causes bacterial
dysentery by invading and colonizing the colonic mucosa, which leads to
intestinal disruption. Shigella spp are also known to decrease beneficial bacteria
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such as Lactobacillus spp [193]. On the other hand, a normally commensal E.
coli bloom can be triggered by an inflammatory host response, which is present
during CHI [194]. Electron acceptors such as nitrate that are produced as a byproduct of the inflammatory host response allow anaerobic gut bacteria such as
E. coli to expand uncontrollably. This could be a reason we see the bloom of E.
coli after injury [194].

By 1.5 months post injury, higher levels of pathobionts such as
Turicibacter spp, which is known to contribute to irritable bowel disease and
colitis, and E coli are present in both CHI and Sham mice [195, 196]. Levels of E.
coli in sham mice have drastically decreased whereas they have stayed mostly
consistent in CHI mice. Although pathobiont bacteria are still present in Sham
mice at this timepoint, there are also higher levels of beneficial bacteria as well,
not seen in CHI. The return to a more balanced microbiome by 1.5 months post
injury in the Sham mice is evidenced by increased levels of the phyla
Bacteroidetes. In the Sham mice, this consists of increased levels of beneficial
bacteria such as Bacteroidetes thetaiotaomicron which plays a critical role in
mediating host mucosal immune response and barrier integrity [197] and
Bacteroidetes ovatus which has immunomodulating abilities, including the
alleviation of LPS induced inflammation [198]. There are also higher levels of
Bifidobacterium which is known to be anti-inflammatory in nature and have antipathogenic qualities [199, 200]. These changes are not seen in CHI control fed
mice. Higher levels of the phyla Bacteroidetes is also seen in the CHI group at
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this point, but this is likely due to increased levels of pathobiont bacteria such as
Parabacteroides diastonis. P. diastonis has been found to play a dichotomous
role in some diseases but mainly works as an aggravator of colitis and
inflammatory bowel disease [201] .

In terms of effects in the brain, we see decreased CBF 3 months
post injury in CHI control fed mice compared to Naïve control mice. As the gut
microbiome is so intertwined with brain vascular integrity [202], it is likely that the
dysbiotic state still present in CHI mice at 3 months post injury is contributing to
the decreased levels of CBF. This could be attributed to decreased levels of
SCFAs such as butyrate, which plays a role in barrier integrity in the gut and
brain. Butyrate is known to increase tight junction proteins in the gut and brain,
leading to less permeable barriers which is ultimately protective of blood flow
[57, 86]. Lower levels of this SCFA could lead to reductions in CBF.

With diet, we saw that inulin caused significant differences in beta
diversity starting at 24 hours post injury and continuing until 3 months post injury.
Beta diversity measures the differences of microbial communities from one
environment compared to another (i.e. how do control fed mice gut microbiomes
differ from inulin fed mice?). This led us to try and understand what bacteria
inulin is selecting for compared to control. At the phyla level, we see higher
levels of Actinobacteria and Firmicutes in inulin fed mice compared to control fed
mice at 24 hours post injury and 1.5 months post injury. This corresponds to the
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species level analysis where inulin fed mice exhibit increased levels of
Lactobacillus spp (part of the Firmicutes phylum) and increased levels of
Bifidobacterium spp (part of the Actinobacteria phylum) compared to control fed
mice. There are no differences between inulin fed groups in terms of increased
beneficial bacteria. This could indicate that inulin is protective of injury effects on
the gut microbiome.

Along with this, inulin fed mice had decreased levels of known
pathobiont bacteria compared to control fed mice. This decrease is consistent
over time, starting at 24 hours post injury and continuing until 3 months post
injury. At 24 hours post injury, Sham and CHI control fed mice showed higher
levels of E. coli and Shigella spp, not seen in inulin fed mice. By 1.5 months post
injury, levels of pathobionts have decreased drastically in Sham control fed mice,
but stayed consistent in CHI control fed mice. CHI mice showed higher levels of
a known opportunistic pathogen Pseudomonas aeurogenosa. P. aeurogenosa is
known to cause a wide array of various life-threatening infections and alter
intestinal barrier function [203, 204]. Other pathobionts also increased including
Desulfovibrio spp which is an intestinal pathogen that can infiltrate the central
nervous system. It was also recently found to play a role in Parkinson’s Disease
[205]. Additionally, Lachnospiraceae spp increased. Lachnospiraceae spp are
part of the Lachnospiraceae family, known to be associated with colitis and
metabolic disorders [162, 163].
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By 3 months post injury, CHI control fed mice show an increase in
pathobionts, including E. coli, Desulfovibrio spp and Streptococcus spp which
causes various diseases [206]. It is likely that the increased levels of beneficial
bacteria had a role in the reduction of the pathobiont bacteria at all timepoints.
Bacteria such as Bifidobacterium pseudolongum and Bifidobacterium animalis
have anti-inflammatory and anti-pathogenic qualities [199, 200] and
Lactobacillus johnsonii and Lactobacillus gasseri are known to be
immunomodulators and inhibit pathogens [199, 207]. Additionally, Lactobacillus
gasseri increased 24 hours post injury in CHI fed mice, but not Sham or Naïve
mice. As we only see this increase in CHI mice, this could potentially identify a
probiotic strain of bacteria that would be benefit those with a mTBI during the
acute period of recovery.

Putatively beneficial bacteria such as Bifidobacterium
pseudolongum, Lactobacillus gasseri and Lactobacillus johnsonii are all known
probiotics[208] . Bifidobacterium spp are acetate producers, and Lactobacillus
spp are propionate and butyrate producers [209]. Both butyrate and propionate
are increased with inulin. Unexpectedly, acetate is seen at higher levels in Naïve
and Sham control groups. This could be because there are higher levels of
acetate producing bacteria in Naïve and Sham control fed mice such as
commensal Streptococcus species. Streptococcus salivarius, Streptococcus
macedonius and Streptococcus thermophilus are seen at higher levels in Naïve
and Sham mice at this timepoint, but not CHI. Additionally, interconversion of
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SCFAs from acetate to butyrate occurs at a high level in the cecum, which points
to microbial cross feeding [50]. Because we see higher levels of Bifidobacterium
in inulin fed mice than control fed mice, but lower levels of acetate, this could
also be an explanation.

It is also possible that inulin fed mice have lower levels of acetate
because it is used by oligodendrocytes to produce myelin, an essential
component of white matter [210, 211]. At 1.5 months post injury and 3 months
post injury we see increased white matter integrity (indexed by FA) in inulin fed
mice compared to control fed mice. At 1.5 months post injury, inulin increased
FA in the left corpus callosum. This white matter tract integrates and transfers
information from both cerebral hemispheres to process sensory, motor and
cognitive signals [212]. Traumatic brain injury has been found to cause lesions
and demyelination in the corpus callosum [212]. The left external capsule also
showed increased FA. The external capsule is the route for cholinergic fibers
from the forebrain to the cortex [213]. Decreased FA in the external capsule has
repeatedly been shown after mTBI [214, 215]. By three months post injury,
inulin also increased FA in the right corpus callosum, left external capsule and
right internal capsule. The right internal capsule is an avenue for communication
between the cerebral cortex and brain stem. The decreased levels of acetate in
inulin fed groups could correspond to the increased levels of white matter
integrity, as acetate is needed to produce myelin [211].

125

Short chain fatty acids also play a role in barrier integrity in the gut
and brain. These metabolites are known to increase expression of tight junction
proteins in the gut and brain, leading to less permeable barriers [57]. A less
permeable blood brain barrier is protective of blood flow [86]. This is evidenced
by the increased levels of cerebral blood flow seen in the hippocampus of CHI
inulin fed mice compared to control fed mice at 3 months post injury. The gut
microbiome is directly related to this, as Lactobacillus spp, which are butyrate
producers, are increased with inulin supplementation. Butyrate plays a direct role
in the increased expression of tight junction proteins [47]. This could also help
explain why we see lower CBF in control mice 3 months post injury, as butyrate
is seen at much lower levels.

A limitation of this study is that only male mice were used. In future
studies, female mice will be included to better understand sex effects on injury
and diet. Additionally, although we believe the transient dysbiosis in Sham mice
comes primarily from anesthetic inhalation, a study that further elucidates the
changes seen in Sham mice needs to be conducted.

In summary, we found that CHI induced dysbiosis by increasing
pathobiont bacteria and disrupting diversity. Along with this, CHI reduced
cerebral blood flow in control fed mice. Prophylactic inulin supplementation
beneficially effects the gut microbiome by reducing putatively pathobiont
bacteria, increasing putatively beneficial bacteria, increasing SCFAs levels in
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cecal contents, increasing white matter integrity and increasing cerebral blood
flow in CHI mice. Taken together, feeding inulin prior to injury may be beneficial
in reducing the acute and long-term effects of CHI. This study may have
profound implications for therapeutics pertaining to head injury.
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Table 4-1. Diet Composition
Diet
Protein %
Carbohydrate %
Fat %
Fiber %
Energy (kcal/g)

Prebiotic Diet
18.2
59.1 (w/o inulin)
8.9 from inulin
7.1
8.0 (Inulin)
4.08
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Control Diet
18.2
60.2 (w/o inulin)
7.1
8.0 (Cellulose)
3.78

Table 4-1. Comparison of diet composition of the Prebiotic (inulin) diet and
Control (cellulose) diet.
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Figure 4-1. Study design.
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Figure 4-1. Study design. Mice started diet (control or inulin) 2 month prior to
injury at 2 months of age. They were given a CHI at 4 months of age (after 2
months of diet administration). Fecal samples were taken periodically throughout
the study at (1) 2 months of age (prior to diet administration), (2) 24 hours prior to
injury, (3) 24 hours post injury, (4) 1.5 months post injury and (5) 3 months post
injury. Diffusion tensor imaging was taken at 1.5 months post injury and 3 months
post injury. Cerebral blood flow was taken 3 months post injury. Active avoidance
behavioral paradigm was run 2.5 months post injury.
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Injury Effects
Figure 4-2. Alpha and beta diversity analysis 24 hours post-injury.
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Figure 4-2. Alpha diversity and beta diversity analysis 24 hours post-injury.
(A) Generalized linear model index results show that injury is having an effect
(F(2,67) = 3.6375, p = 0.0319). Pairwise comparisons using Shannon index
alpha diversity shows that in the control group sham animals shows a reduced
alpha diversity compared to the naïve group (p = 0.044). (B) Bray-Curtis beta
diversity analyses showed there was a significant difference at 24 hours post
2

injury due to injury (Sum of Squares = 0.146183, R = 0.133, F = 6.80864, p =
0.001). Pairwise analysis indicated differences between naïve control vs. sham
control (p = 0.001) and naïve control vs. CHI control (p = 0.001).
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Figure 4-3. Phyla level analysis 24 hours post injury and 1.5 months post
injury.

Figure 4-3. Phyla level analysis 24 hours post injury and 1.5 months post
injury. At (A) 24 hours post injury higher levels of Verrucomicrobia (Sham vs.
Naïve Q = 1.65e-03, CHI vs. Naïve Q = 7.78e-03), and Bacteroidetes (Sham vs.
Naïve Q = 3.71e-06, CHI vs. Naïve Q = 8.07e-04) are seen in Sham and CHI
compared to naive. Higher levels of Proteobacteria (Sham vs. Naïve Q = 1.21e02) are seen in the Sham group compared to the Naïve. At (B) 1.5 months post
injury higher levels of Bacteroides are seen in Sham compared to CHI and Naïve
(Sham vs. Naïve Q = 0.04, Sham vs. CHI Q = 0.05).
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Figure 4-4. Pathobiont bacteria increased 24 hours post injury and 1.5 mpi
in Sham control and CHI control groups.
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Figure 4-4. Pathobiont bacteria increased 24 hours post injury and 1.5 mpi
in Sham control and CHI control groups. Pathobiont bacteria significantly
bloom compared to the naïve control group (A) 24 hours post injury in the sham
control group (S. dysenteriae Q = 2.23e-04, S. flexneri Q = 1.64e-04, S. boydii Q
= 1.35e-05, E. coli Q = 5.03e-07, Escherichia other Q = 3.00e-06, A. muciniphila
Q = 0.02) and in the CHI group (S. dysenteriae Q = 2.92e-05, S. flexneri Q =
0.01, S. boydii Q = 5.82e-05, E. coli Q = 1.12e-05, Escherichia other Q = 4.53e05, A. muciniphila Q = 0.05, P. distasonis Q = 6.10e-03). By (B) 1.5 mpi
pathobiont bacteria are still present in the Sham control group
(Turicibacteraceae; Other;Other Q = 0.03, E. coli Q = 0.05) and CHI control
group (Turicibacteraceae; Other;Other Q = 0.03) compared to the naïve control
mice.
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Figure 4-5. Beneficial bacteria increased in Sham control fed mice 1.5
months post injury, but not CHI control fed mice.
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Figure 4-5. Beneficial bacteria increased in Sham control fed mice 1.5
months post injury, but not CHI control fed mice. Beneficial bacteria increase
1.5 months post injury in sham mice compared to CHI mice including B. other (Q
= 4.55e-04), B. pseudolongum (Q = 3.14e-03), B. ovatus (Q = 1.55e-03) and B.
thetaiotaomicron (Q = 1.27e-03)
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Figure 4-6. Cerebral blood flow is affected 3 months after injury in CHI
control mice.

D

C
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Figure 4-6. Cerebral blood flow is affected 3 months after injury in CHI
control mice. Pairwise comparisons showed a significant decreased in CBF in
the CHI control group compared to the Naïve control group in the (A) left
proximal cortex (p = 0.0231*), (B) right hippocampus (p = 0.0496*), (C) left
thalamus (p = 0.0449*) and (D) right thalamus (p = 0.0324*). Data are mean ±
SD.
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Diet analysis
Figure 4-7. Alpha diversity and beta diversity analysis 24 hours, 1.5
months, and 3 months post-injury.
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Figure 4-7. Alpha diversity and beta diversity analysis 24 hours, 1.5 months
and 3 months post-injury. Shannon index is used for all alpha diversity
analyses and Bray-Curtis index is used for all beta diversity analyses. (A) 24
hours post injury, alpha diversity shows no differences due to diet. (B) 1.5
months post injury, diet is having an effect (F(1,66) = 4.437, p = 0.0391).
Pairwise comparisons show a significant decrease in alpha diversity between
Naïve control vs. Inulin (p = 0.013) and CHI control vs. CHI inulin (p = 0.033). (C)
3 months post injury, alpha diversity shows no differences due to diet. (D) 24
hours post injury, Beta diversity showed there was a significant difference due to
diet (Sum of Squares = 0.213789, R2 = 0.194, F = 19.9148, p = 0.001). Pairwise
analysis indicated significant differences between the Naïve control and Naïve
inulin (p = 0.001) and the Sham control and Sham Inulin (p = 0.001) and CHI
control and CHI inulin (p = 0.001). (E) 1.5 months post injury, Beta diversity again
showed there was a significant difference due to diet (Sum of Squares =
0.34854, R2 = 0.331, F = 34.352, p = 0.001). Pairwise analysis indicated
differences between the Naïve control and Naïve inulin (p = 0.001) and the Sham
control and Sham Inulin (p = 0.001) and CHI control and CHI inulin (p = 0.001).
(F) 3 months post injury, Beta diversity continued to show a significant difference
due to diet (Sum of Squares = 0.30966, R2 = 0.386, F = 41.1556, p = 0.001).
Pairwise analysis indicated significant differences between the Naïve control and
Naïve inulin (p = 0.001) Sham control and Sham Inulin (p = 0.001) and CHI
control and CHI inulin (p = 0.001)
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Figure 4-8. Phyla level analysis 24 hours, 1.5 months, and 3 months post
injury.
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Figure 4-8. Phyla level analysis 24 hours, 1.5 months and 3 months post
injury. At (A) 24 hours post injury there are higher levels of Actinobacteria in
inulin fed mice compared to control (Naïve control vs. Inulin Q = 3.86e-04, Sham
control vs. Inulin Q = 3.58e--03, CHI control vs. inulin Q = 1.56e-08). Firmicutes
also see higher levels in inulin fed mice compared to control (Naïve control vs.
Inulin Q = 1.44e-06, Sham control vs. Inulin Q = 1.16e-08, CHI control vs. inulin
Q = 1.06e-09). At (B) 1.5 months post injury higher levels of Actinobacteria are
seen in inulin mice compared to control (Naïve control vs. Inulin Q = 1.19e-04,
Sham control vs. Inulin Q = 4.40e-05, CHI control vs. inulin Q = 2.44e-07).
Firmicutes also show higher levels in inulin compared to control fed mice (Naïve
control vs. Inulin Q = 6.29e-08, Sham control vs. Inulin Q = 1.07e-08, CHI control
vs. inulin Q = 3.35e-04). At (C) 3 months post injury higher levels of Firmicutes
inulin fed mice compared to control (Naïve control vs. Inulin Q = 9.88e-06, Sham
control vs. Inulin Q = 5.32e-13, CHI control vs. inulin Q = 484e-03)
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Figure 4-9. Analysis of pathobiont bacteria at 24 hours, 1.5 months and 3
months post injury modified by diet.
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Figure 4-9. Analysis of pathobiont bacteria at 24 hours, 1.5 months and 3
months post injury modified by diet. At (A) 24 hours post injury control fed
mice show higher levels of E. coli and Shigella spp than inulin fed mice in Sham
(E. coli Q = 4.15e-08, S. dysenteriae Q = 2.14e-04 , S. flexerni Q = 2.66e-05 , S.
boydii Q = 2.91e-06) and CHI (E. coli, Q = 1.86e-08, S. dysenteriae Q = 1.39e04, S. flexerni Q = 0.04 , S. boydii Q = 2.02e-05). At (B) 1.5 months post injury
control fed mice show higher levels than inulin fed mice of L. bacterium 28-4 and
Desulfovibrio spp in Naïve (L bacterium 28-4 Q = 1.50E-15, D. piger Q = 0.01, D.
other Q = 3.05e-03), Sham (L bacterium 28-4 Q = 9.01e-08, D. other Q = 0.02)
and CHI (L bacterium 28-4 Q = 6.33E-19, D. piger Q = 5.01e-03, D. other Q =
0.01) and higher levels of P. aeurgoenosa in Naive (Q = 3.13e-03) and CHI (Q =
0.02). At (C) 3 months post injury there are higher levels in control fed mice than
inulin fed mice of L. bacteria 28-4 and Streptococcus spp in Naïve (L. bacterium
28-4 Q = 7.55E-10, S. pyogenes Q = 3.86e-03), Sham (L. bacterium 28-4 Q =
7.55E-10) and CHI (L. bacterium 28-4 Q = 3.26E-17, S. suis Q = 0.03, S.
pyogenes Q = 5.45e-05) higher levels of Desulfovibrio spp in Sham (D. piger Q =
1.06e-06, D. other Q = 1.91e-06) and CHI (D. piger Q = 4.42e-04, D. other Q =
0.03) and higher levels of E. coli, Shigella spp and P. aeurogenosa in CHI mice
(E. coli Q = 1.79e-03, S. dysenteriae Q = 0.04 , S. other Q = 2.14e-12, S. boydii
Q = 0.02, P. aeruginosa Q = 1.67e-05)
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Figure 4-10. Analysis of beneficial bacteria at 24 hours, 1.5 months and 3
months post injury modified by diet.
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Figure 4-10. Analysis of beneficial bacteria at 24 hours, 1.5 months and 3
months post injury. At (A) 24 hours post injury inulin fed mice show higher
levels than control fed mice of Bifidobacterium spp in Naïve (B. other Q = 4.19e04), Sham (B. other Q = 2.89e-06, B. pseudolongum Q = 3.48e-04) and CHI (B.
other Q = 1.63E-23, B. pseudolongum Q = 1.34E-34) and higher levels of
Lactobacillus spp in CHI mice (L. gasseri Q = 5.14e-03). At (B) 1.5 months post
injury inulin fed mice show higher levels than control fed mice of Bifidobacterium
spp in Naïve (B. other Q = 1.35e-05 , B animalis Q = 1.75e-04 and B.
pseudolongum Q = 1.37e-03), Sham (B. other Q = 3.98e-08 , B animalis Q =
2.53e-07 and B. pseudolongum Q = 8.97e-06, B. bifidum Q = 1.93e-04) and CHI
(B. other Q = 2.93E-43 , B animalis Q = 2.43E-25 and B. pseudolongum Q =
1.40E-26) and higher levels of Lactobacillus spp. in Sham (L. gasseri Q = 0.01, L.
johnsonii Q = 0.03) and CHI (L. gasseri Q = 7.53e-05, L. johnsonii Q = 1.21e-06).
At (C) 3 months post injury inulin fed mice show higher levels than control fed
mice of Bifidobacterium spp. in Naïve (B. other Q = 4.52e-05, B. animals, Q =
7.18e-05, B. pseudolongum Q = 4.74e-03), Sham (B. other Q = 1.46e-05, B
animalis Q = 2.23e-04, B. pseudolongum Q = 6.07e-04, B. bifidum Q = 2.46e-03)
and CHI (B. other Q = 1.49e-06, B animalis Q = 4.24e-06 and B. pseudolongum
Q = 3.38e-05, B. bifidum Q = 6.75e-03) and higher levels of Lactobacillus spp in
Sham (L. johnsonii Q = 0.03) and CHI (L. gasseri Q = 3.75e-03).
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Figure 4-11. SCFA analysis 3 months post injury.
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Figure 4-11. SCFA analysis 3 months post injury. (A) Acetate showed a
significant effect due to diet (F(1,64) = 20.10, p < 0.0001). Pairwise comparisons
showed acetate significantly increased in the control fed mice compared to the
inulin fed mice in the Naïve (p = 0.0052**) and Sham (p = 0.0118**) groups. (B)
Butyrate showed a significant effect due to diet (F(1,64) = 126.8, p < 0.0001).
Pairwise comparisons showed butyrate significantly increased in inulin fed mice
compared to control fed mice in Naïve (p < 0.0001****), Sham (p < 0.0001****)
and CHI (p = 0.0001***). (C) Propionate showed a significant effect due to diet
(F(1,64) = 9.556, p = 0.003). Pairwise comparisons showed propionate increased
in inulin fed mice compared to control fed mice in Sham (p = 0.0432*) and CHI (p
= 0.0482*). Data are mean ± SD.
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Figure 4-12. Diffusion tensor imaging analysis 1.5 months post injury.
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Figure 4-12. Diffusion tensor imaging analysis 1.5 months post injury. The
(A) Left corpus callosum showed a significant effect due to diet (F(1,29) = 4.416,
p = 0.044. Pairwise comparisons did not show any significant differences. The
(B) Left external capsule showed a significant effect due to diet (F(1,29) = 4.210,
p = 0.0493. Pairwise comparisons showed increased FA in inulin fed mice
compared to control fed mice in the Naïve group (p = 0.0362*). Data are mean ±
SD.
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Figure 4-13. Diffusion tensor imaging analysis 3 months post injury.
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Figure 4-13. Diffusion tensor imaging analysis 3 months post injury. The (A)
Right corpus callosum showed a significant effect due to diet (F(1,57) = 4.69, p =
0.0345). Pairwise comparisons indicated higher FA in Sham inulin fed mice
compared to control fed mice (p = 0.0461*). The (B) Right internal capsule
showed a significant effect due to diet (F(1,57) = 5.125, p = 0.0274), Pairwise
comparisons indicated higher FA in CHI inulin fed mice compared to control fed
mice (p = 0.0317*). In the (C) Left external capsule pairwise comparisons
indicated higher FA in Sham inulin fed mice compared to control fed mice (p =
0.0228*). Data are mean Data are mean ± SD.
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Figure 4-14. Cerebral blood flow 3 months post injury.
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Figure 4-14. Cerebral blood flow 3 months post injury. Pairwise comparisons
in the right hippocampus showed a significant increase in CBF in the CHI inulin
group compared to the CHI control group in the right hippocampus (p = 0.0309*).
Data are mean ± SD.
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CHAPTER 5. GENERAL DISCUSSION

Taken together, this dissertation provides evidence that dietary
inulin could be beneficial in mitigating symptoms of mTBI, a risk factor for AD,
and AD itself, through targeting the gut brain axis. As there are currently no drug
therapeutics for mTBI and very few for AD [40, 41], these results may have
profound implications for developing therapeutics or preventive interventions in
the future.
This dissertation is the first to look at the effects of mTBI on the gut
microbiome past the acute phase of injury recovery. We found that CHI induced
dysbiosis by increasing pathobiont bacteria and disrupting diversity through the
chronic phase of injury. Along with this, CHI was found to reduce cerebral blood
flow and white matter integrity into the chronic phase, which is consistent with
the literature [27, 28]. These findings are important in propelling forward the field
of mTBI research involving the gut brain axis. Studies must look past the acute
phase of injury in order to understand the full effects of brain injury on the gut
microbiome.

Another important part of these studies revealed that sham and
CHI mice have their own unique patterns of dysbiosis. Previously, sham mice
had been used as a control group in mTBI studies, however, our studies reveal
that naïve mice must be included in order to have a true control group. Sham
mice show a transient dysbiotic state seen 24 hours post injury and normalizing
by 1.5 months post injury. However, in CHI mice we see a more gradual
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transition into a dysbiotic state with dysbiosis peaking 3 months post injury. We
believe that the transient dysbiotic state seen in sham mice is due to anesthetic
inhalation. This highlights the importance of including a naïve group which does
not undergo injury or anesthetic of any kind in order to fully understand the
changes occurring.
We also show that inulin supplementation prophylactically, or
during the chronic period of injury is beneficial in improving the effects of mTBI.
Inulin supplementation beneficially effects the gut microbiome by reducing
putatively pathobiont bacteria, increasing putatively beneficial bacteria,
increasing SCFAs levels in cecal contents and plasma, increasing white matter
integrity and increasing cerebral blood flow in CHI mice. These results are
important as they have implications for those at risk for head injury, such as
athletes and military personnel, as well as those suffering from long term
symptoms after mTBI as there is currently no therapeutics.

Although these studies give us a big picture idea of the effects of
mTBI on the gut brain axis, more studies need to be done to understand the
mechanistic effects. For example, we see that inulin supplementation increases
blood flow in various brain regions when administered prophylactically and
chronically after injury. We know that the brain communicates with the gut
through neurons [180], and neurons and astrocytes control brain blood flow
[216]. Other diets have been shown to increase cerebral blood flow. For
example, the ketogenic diet increases CBF through acute increases in ketone
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body levels in rats and humans [86]. Additionally, studies in germ free mice
prove the gut microbiome to be an important mediator in the vascular system
with commensal bacteria being essential for vascular homeostasis [217].
However, the mechanism by which dietary fiber increases cerebral blood flow
still needs to be investigated and uncovered.
Our mTBI studies in male wild type mice are important in
establishing a basic understanding the injury effects on the gut brain axis.
However, humans are much more complex in terms of gender and genetics. This
line of studies in mTBI must be expanded to include not only females, but
genotypes that show a compounded risk for AD with mTBI, such as APOE4
[218]. The study pertaining to AD in this dissertation highlights the importance of
taking genotype into account when studying nutritional interventions. When
administered as a preventative supplement for AD, inulin had systemic benefits
in E3FAD and E4FAD mice. However, each genotype showed different
responses to the diet. For example, E3FAD mice showed altered tryptophan and
tyrosine metabolism whereas E4FAD mice showed altered TCA and PPP
metabolism, which relates to decreased glucose metabolism systemically years
before the onset of AD [43]. It is clear from this study that genotype needs to be
taken into account when studying dietary interventions, as nutrigenetics is an
important factor that needs to be better understood.
Taken together, this dissertation provides important evidence
which will propel the field of dementia prevention forward. We show the
importance of looking past the acute phase of mTBI when assessing the effects
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of injury on the gut mcirobiome, including a naïve cohort and that dietary
intervention prophylactically and chronically can be beneficial in mTBI recovery.
We also show the importance of understanding the role of nutrigenetics when
assessing nutritional interventions be it in studies of AD or mTBI. Relating to
nutrigenetics, we show inulin supplementation benefits both E3FAD and E4FAD
mice differently when given as a preventative nutritional intervention in an AD
mouse model. These studies may inform future preventative and rehabilitation
efforts in mTBI and AD, as many people suffer from long term symptoms and
there are currently no known therapies. To fully understand the implications of
these studies, clinical trials must be conducted. The methods used in our study
are already used in humans (i.e., MRI imaging, gut microbiome sequencing and
dietary fiber supplements) making our studies highly translational. In the future,
those at risk for head injury or with an APOE4 allele may consider a high fiber
diet as a preventative mechanism if human studies show the same promising
results.
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Abstract
Caloric restriction (CR) has been shown to extend longevity and

protect brain function in aging. However, the effects of CR in young adult mice
remain largely unexplored. In addition to the fundamental, long-term changes,
recent studies demonstrate that CR has a significant impact on transient,
postprandial metabolic flexibility and turnover compared to control groups. The
goal of the study was to identify the brain metabolic changes at a transient (2
hour) and steady (6 hour) postprandial state in young mice (5-6 months of age)
fed with CR or Ad Libitum (AL; free eating). Using metabolomics profiling, we
show that CR mice had significantly higher levels of neurotransmitters (e.g.,
glutamate, N-acetylglutamate), neuronal integrity markers (e.g., NAA and
NAAG), essential fatty acids (e.g., DHA and DPA), and biochemicals associated
carnitine metabolism (related to reduced oxidative stress and inflammation) in
the cerebral cortex and hippocampus at 2-hrs. These biochemicals remained at
high levels at the 6-hr postprandial time-point. The AL mice did not show the
similar increases in essential fatty acid, and carnitine metabolism until the 6-hr
time-point, and failed to show increases in neurotransmitters and neuronal

162

integrity markers at any time-point. On the other hand, metabolites related to
glucose utilization – glycolysis and pentose phosphate pathway (PPP) – were
low in the CR mice throughout the 6-hr period and significantly increased at the
6-hr time-point in the AL mice. Our findings suggest that CR induces distinct
postprandial responses in metabolites that are essential to maintain brain
functions. CR mice produced higher levels of essential brain metabolites in a
shorter period after a meal and sustained the levels for an extended period,
while maintaining a lower level of glucose utilization and better glycemic control.
These early brain metabolism changes in the CR mice might play a critical role
for neuroprotection in aging. Understanding the interplay between dietary
intervention and postprandial metabolic responses from an early age may have
profound implications for impeding brain aging and reducing risk for
neurodegenerative disorders.

6.2

Introduction
Caloric restriction (CR), without malnutrition, has been

demonstrated repeatedly to extend lifespan in various species [219]. A large
body of evidence shows that CR protects brain functions with age, preserves
memory in older adults and aging mice, and that CR-treated animals had lower
incidence of age-related neurodegenerative disorders, including Alzheimer’s
disease [220, 221]. In particular, the protective mechanism of CR in aging has
been suggested to be associated with preservation of neuronal activity, brain
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metabolic and vascular functions, white matter integrity (WMI), and mitigation of
oxidative stress and neuroinflammation [154, 156, 222-226]

The impacts of CR on brain function at an early age are largely
unexplored, however. We were interested to know if CR also made significant
effects in young adult mice that might be associated with the neuroprotection
seen with aging, including metabolites related to neurotransmitters, WMI,
glycolysis and inflammation. Further, the metabolic changes induced by CR may
also be postprandial time-dependent. Recent studies demonstrated that
individuals with CR had significant differences in transient, postprandial
metabolic flexibility and turnover compared to the control groups [227-229].
Therefore, in addition to the fundamental, long-term changes, it will also be
important to identify the energy production at different postprandial stages.

In this study, our goal was to identify the brain metabolic changes
at transient (2 hour) and steady (6 hour) postprandial states between young mice
fed with CR or Ad Libitum (AL; free eating). We used metabolomics profiling to
determine the levels of metabolites of interests. We focused on the brain regions
that are highly associated with cognitive functions in rodents, including cerebral
cortex and hippocampus. We hypothesized that CR may have significant effects
on postprandial brain metabolism in young mice.
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6.3

Materials and Methods

6.3.1 Animals

We obtained male C57BL/6N mice from the National Institute of
Aging (NIA) Caloric Restriction Colony with groups of young adult mice (5-6
months of age) [230] fed with either AL or CR diet (N= 14 for each group). The
40% CR was administrated to the animals by week 16 and the diet was
continued over the lifetime. The vitamin-fortified NIH-31 (NIH-31 fortified) diet fed
to CR mice provided 60% of the calories and additional vitamins supplement
consumed by ad libitum mice. After arriving at our facilities, mice were housed
individually (1 mouse per cage) in a specific pathogen-free facility. The CR mice
were fed a pellet of the CR diet between 7 a.m. and 9 a.m. everyday. The mice
were situated for 3-4 weeks before sending for brain extracts. All experimental
procedures were performed according to NIH guidelines and approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of
Kentucky (UK).

6.3.2 Metabolomics Profiling

Brain tissue from the cerebral cortex and hippocampus was
extracted and homogenized for metabolic profiling. Half of the group (N = 7) was
subjected under 2-hour and the other half under 6-hour postprandial brain tissue
collection. Brain samples were sent to Metabolon Inc. for biochemical profiling
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and statistical analysis. Metabolon’s standard solvent extraction method was
used to prepare the samples, which were then equally split for analysis via liquid
chromatography/mass spectrometry (LC/MS) or gas chromatography/mass
spectrometry (GC/MS) using their standard protocol [111].

6.3.3 Mass Spectrometry Analysis

Non-targeted UPLC-MS/MS and GC-MS analyses were performed
at Metabolon, Inc. The UPLC/MS/MS portion of the platform incorporates a
Waters Acquity UPLC system and a Thermo-Finnegan LTQ mass spectrometer,
including an electrospray ionization (ESI) source and linear ion-trap (LIT) mass
analyzer. Aliquots of the vacuum-dried sample were reconstituted, one each in
acidic or basic LC-compatible solvents containing 8 or more injection standards
at fixed concentrations (to both ensure injection and chromatographic
consistency). Extracts were loaded onto columns (Waters UPLC BEH C18-2.1 x
100 mm, 1.7 μm) and gradient-eluted with water and 95% methanol containing
0.1% formic acid (acidic extracts) or 6.5 mM ammonium bicarbonate (basic
extracts). The instrument was set to scan 99–1000 m/z and alternated between
MS and MS/MS scans.

Samples destined for analysis by GC-MS were dried under vacuum
desiccation for a minimum of 18 h prior to being derivatized using
bis(trimethylsilyl)trifluoroacetamide (BSTFA) as described [231]. Derivatized
samples were separated on a 5% phenyldimethyl silicone column with helium as
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carrier gas and a temperature ramp from 60° to 340°C within a 17-min period.
All samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole MS operated at unit mass resolving power with electron
impact ionization and a 50–750 atomic mass unit scan range. The instrument is
tuned and calibrated for mass resolution and mass accuracy daily.

6.3.4 Compound Identification, Quantification and Data Curation

Metabolites were identified by automated comparison of the ion
features in the experimental samples to a reference library of chemical standard
entries that included retention time, molecular weight (m/z), preferred adducts,
and in-source fragments as well as associated MS spectra and curated by visual
inspection for quality control using software developed at Metabolon [232].
Identification of known chemical entities was based on comparison to
metabolomic library entries of more than 2,800 commercially-available purified
standards. Subsequent QC and curation processes were utilized to ensure
accurate, consistent identification and to minimize system artifacts, misassignments, and background noise. Library matches for each compound were
verified for each sample. Peaks were quantified using area under the curve.
Raw area counts for each metabolite in each sample were normalized to correct
for variation resulting from instrument inter-day tuning differences by the median
value for each run-day, therefore setting the medians to 1.0 for each run. This
preserved variation between samples, but allowed metabolites of widely different
raw peak areas to be compared on a similar graphical scale.
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6.3.5 Bioinformatics

The LIMS system encompasses sample accessioning, preparation,
instrument analysis and reporting, and advanced data analysis. Additional
informatics components include data extraction into a relational database and
peak-identification software; proprietary data processing tools for QC and
compound identification; and a collection of interpretation and visualization tools
for use by data analysts. The hardware and software systems are built on a
web-service platform utilizing Microsoft’s .NET technologies, which run on highperformance application servers and fiber-channel storage arrays in clusters to
provide active failover and load balancing.

6.3.6 Data Analysis

Log transformations and imputation of missing values with the
minimum observed values for each metabolite was performed. Welch’s twotailed t-test to was used to identify biochemicals that were significantly different
between groups. Levels of statistical significance were reached when p < 0.05.

6.4

Results
Table 5-1 summarizes the category and function of the metabolites

that we found significantly different between the CR and AL mice. At the 2-hr
postprandial time-point, CR mice had significantly higher levels in
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neurotransmitters, neuronal integrity markers, essential fatty acids, and
biochemicals associated with carnitine metabolism compared to the AL mice
(Table 5-2, column 1; CR vs. AL at 2-hr). As for neurotransmitters, the CR
mice had significantly higher levels in glutamate, N-acetylglutamate, glycine, and
serine [233, 234]. Glutamate is an excitatory neurotransmitter and associated
with cognitive function [235]; glycine and serine (a precursor of glycine) are
inhibitory neurotransmitters [236]. Glycine is also anti-inflammatory,
cytoprotective, and immunomodulating [235].

N-acetyl-aspartate (NAA) and N-acetyl-aspartyl-glutamate (NAAG)
were also found significantly higher in the CR mice at the 2-hr time-point. NAA
and NAAG have been used as markers for neuronal integrity as they are most
abundant in neurons and are also used as an index of neuron quantity [234]; the
reduction of these two metabolites have been associated with brain aging and
neurodegenerative disorders [237].

CR mice also showed higher levels in dihomo-linolenate (20:3n3 or
n6), docosapentaenoate (n3 DPA; 22:5n3), docosapentaenoate (n6 DPA;
22:5n6) and docosahexaenoate (DHA; 22:6n3) at the 2-hr time-point. These are
Omega-3, polyunsaturated fatty acids [238]. DHA helps with cell membrane
structure, assists in normal growth and development, and participates in key
pathways of the immune system [239]. DPA is often considered the third most
prevalent omega-3 fatty acid found in fish oil, following DHA and EPA
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(eicosapentaenoate) [240]. Carnitine-related metabolites, such as carnitine,
palmitoylcarnitine, stearoylcarnitine, and oleoylcarnitine were also higher in the
CR mice [241] . As carnitine participates in the transport of long-chain fatty acids
into the mitochondrial matrix, an increase in these metabolites might indicate
facilitation in this transport function and reduced oxidative stress [242].

Interestingly a similar pattern of metabolite increases were not
found in the AL mice until the 6-hr postprandial time-point (Table 5-2, column 2;
AL, 6-hr vs. 2-hr). Moreover, some of the metabolites, though increased, did not
reached significance, such as glutamate, N-acetylglutamate, NAA, NAAG. The
results suggest that AL mice may be not as effective in producing these
metabolites after a meal, especially those related to improving neuronal integrity
and glycemic control.

We further examined the metabolic profile between CR and AL
mice at 6-hr time-point. At this stage, no significant differences were found in the
levels of neurotransmitters, essential fatty acids and glycolytic intermediates
between the two groups, except dihomo-linolenate (20:3n3 or n6) and
docosapentaenoate (n3 DPA; 22:5n3) (Table 5-2, column 3; CR vs. AL at 6hr). As these metabolites had an early rise (at 2-hr) in the CR group and
followed by the AL group at 6-hr, the results indicated that CR mice might have
been able to maintain high levels of these metabolites over the 4-hour
postprandial period.
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On the other hand, we found that CR mice had maintained stable
levels of glycolytic metabolites over the postprandial period (Table 5-3).
Specifically, glucose-6-phosphate (G6P), fructose-6-phosphate, and lactate
stayed constant in the CR mice, whereas they significantly increased at 6-hr in
the AL mice; glucose was also higher in AL mice at 6-hr compared to 2-hr, but
did not reach significance. A similar pattern was found with alanine, an amino
acid produced from pyruvate (a product of glycolysis), as well as metabolites
associated with pentose phosphate pathway (PPP), including arabitol and
xyulose-5-phosphate and ribulose-5-phosphate [243].

6.5

Discussion
Caloric restriction is perhaps the most studied intervention that

slows down aging and extends longevity since the 1930s [244] . CR has been
shown to enhance health span and retard aging phenotypes in various systems,
including the brain [245]. In this study, we further demonstrated that CR also has
significant impacts in young animals, especially the distinct postprandial pattern
in brain metabolism compared to AL controls. CR mice produced higher levels of
many metabolites in a shorter period after a meal, and sustained the levels for
an extended period of time. The metabolites included neurotransmitters,
neurotrophic factors, essential fatty acids, and carnitine-related metabolism
(related to immune function and reduced oxidative stress). The AL mice did not
show the similar increases in essential fatty acids and carnitine metabolism until
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the 6-hr time-point, but failed to show increases in neurotransmitters and
neuronal integrity markers at any time-point. The findings suggest that CR mice
might produce these metabolites more effectively after a meal, especially those
related to cognitive functions.

On the other hand, CR mice showed constant lower levels of
glucose utilization compared to AL mice. This is consistent with a previous
findings using PET-18FDG scans that young CR mice had lower glucose uptake
in the brain [156]. Other studies show that lower glucose uptake was
accompanied by higher fatty acids utilization (e.g., ketone bodies), and that this
brain metabolic change is preserved with age [154].

Our findings are consistent with Dhahbi et al’s observations of
postprandial responses in metabolic enzyme level induced by CR [229]. They
showed that CR caused a reduced enzymatic capacity for glycolysis which is
consistent with our findings that glycolysis is not up regulated after feeding in CR
mice. Dhahbi et al. also reported an increase in insulin sensitivity in the CR
animals, which is also consistent with our finding of improved glycemic control of
the CR mice. Further, they found increased activity of glutaminase, an enzyme
that converts glutamine to glutamate. This is in line with our observation that CR
mice had higher postprandial glutamate levels compared to the AL mice.
Collectively, our results are consistent with previous findings that CR altered
postprandial patterns in glycolysis, and neurotransmitter production.
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The findings from the current study led us to speculate that the
early changes we saw in the brain metabolites might be associated with the
neuroprotective factors seen in aged animals. Indeed, old animals with CR have
been shown to have preserved glutamate-glutamine neurotransmission cycling
[225], cell structure of white matter [156], cognitive functions [237], and reduced
neuroinflammation and oxidative stress [246], and lower incidence for
Alzheimer’s disease [247, 248]. This is also in line with a previous report that
early enhancement of cerebral blood flow (CBF) in young mice is associated with
CBF preservation in aging mice [226]. In other words, the protective effects of
CR seen in the aging animals may be manifested as an enhancing factor in
young mice. As brain integrity plays a major role in determining lifespan [249],
our findings imply the brain metabolic changes observed in the young CR mice
may be a critical factor that contributes to the extended lifespan and health span
phenomenon that has been repeatedly observed under CR condition.

A limitation of the present study is that we only used male mice;
therefore, we were not able to investigate sex effects in the study. Another
limitation is that we used a long-lived rodent model. Recent studies have shown
that the lifespan response to CR may vary widely in mice from different genetic
backgrounds [250]. In some cases, CR shortened the lifespan in inbred mice. It
will be important in the future to determine if the beneficial effects of CR
observed in the young mice in the current study are still warranted in those short-
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lived inbred mice. Future studies will also need to look into the mechanism of the
postprandial turnover in the CR mice.

In conclusion, we demonstrated that CR induces distinct
postprandial responses in metabolites that are essential to maintain brain
functions, while also maintaining a lower level of glycolysis. Our findings are
consistent with literature that CR enhances postprandial metabolic flexibility and
turnover. These early changes in CR mice might play a critical role for
neuroprotection in aging. Understanding the interplay between dietary
intervention and postprandial metabolic responses from an early age may have
profound implications for impeding brain aging and reducing the risk for
neurodegenerative disorders.
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Roles

Table 6-1. Global list of biochemical mentioned and their roles.
Biochemical
Reference

Neurotransmitters and Neuronal
Integrity markers

Glutamate
Glycine
Serine
N-Acetylglutamate (NAG)

[233], [234] [235] [236]
[237]

N-Acetylaspartate (NAA)
N-Acetylaspartyl-glutamate
(NAAG)
Essential Fatty Acids

Dihomolinolenate (20:3n3 or n6)
Docosapentaenoate (n6 DPA;
22:5n6)

[238], [239], [240]

Docosapentaenoate (n3 DPA;
22:5n3)
Docosahexaenoate (DHA;
22:6n3)
Carnitine-related Metabolites

Carnitine
Palmitoylcarnitine

[241], [242]

Stearoylcarnitine
Oleoylcarnitine
Glucose Metabolism and
Pentose Phosphate Pathway

Glucose
Glucose-6-Phosphate
Fructose-6-Phosphate
[243], [251], [252],
[253]

Lactate
Alanine
Isobar: Ribulose-5-Phosphate,
Xyulose- 5-phosphate
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Table 6-1. Global list of biochemical mentioned and their roles.
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Table 6-2. Distinct postprandial pattern in brain metabolism changes between the CR and AL mice.

Column 1

Fold
Change

2 Hour
Pathway

Column 2

Biochemical

CR
CR

AL
AL

Glutamate
N-acetylglutamate
Neurotransmi
tters
and Neuronal
Metabolites

Glycine
Serine
N-acetylaspartate (NAA)

Essential
Fatty Acids

N-acetyl-aspartylglutamate (NAAG)
Dihomolinolenate
(20:3n3 or n6)
Docosapentaenoate (n6
DPA; 22:5n6)
Docosapentaenoate (n3
DPA; 22:5n3)
Docosahexaenoate
(DHA; 22:6n3)

1.07±
0.092
1.12 ±
0.087
0.987 ±
0.125
1.05 ±
0.082
1.08 ±
0.036
1.34 ±
0.077
0.900 ±
0.058
0.873 ±
0.076
1±
0.109
0.985 ±
0.147

0.921 ±
0.113
0.911 ±
0.224
0.828 ±
0.219
0.852 ±
0.201
0.919 ±
0.144
0.884 ±
0.288
0.727 ±
0.156
0.669 ±
0.130
0.779 ±
0.154
0.690 ±
0.134

1.16
1.23
1.19
1.23
1.18
1.51
1.24
1.3
1.28
1.43

2 Hour

6 Hour

Pvalu
e

AL

AL

0.00
25
0.00
56
0.03
71
0.00
72
0.00
12
0.00
05
0.01
42
0.01
42
0.03
8
0.00
46

0.921 ±
0.113
0.911 ±
0.224
0.828 ±
0.219
0.852 ±
0.201
0.919 ±
0.144
0.884 ±
0.288
0.727 ±
0.156
0.669 ±
0.130
0.779 ±
0.154
0.690 ±
0.134

Fold
Change

Column 3

Signific
ance

Fold
Change

6 Hour

6 hr

CR
P-value

CR

AL

2 hr
1.01 ±
0.087
0.997 ±
0.048
1.02 ±
0.120
1.03 ±
0.131
0.995 ±
0.066
1.11 ±
0.355
1.29 ±
0.173
0.993 ±
0.046
1.38 ±
0.275
1.11 ±
0.183

Signific
ance

P-value
AL

1.1

0.0569

1.09

0.137

1.23

0.0212

1.21

0.017

1.08

0.0917

1.26

0.057

1.78

2.76E07

1.48

0.0008

1.77

5.86E05

1.6

0.0005

1.01 ±
0.068
0.977 ±
0.118
0.943 ±
0.097
0.954 ±
0.135
0.995 ±
0.094
0.974 ±
0.082
1.04 ±
0.107
1.05 ±
0.245
0.896 ±
0.176
0.939 ±
0.212

1.01 ±
0.087
0.997 ±
0.048
1.02 ±
0.120
1.03 ±
0.131
0.995 ±
0.066
1.11 ±
0.355
1.29 ±
0.173
0.993 ±
0.046
1.38 ±
0.275
1.11 ±
0.183

1

0.9729

0.98

0.754

0.92

0.444

0.93

0.3678

1

0.9611

0.88

0.4491

0.81

0.0268

1.05

0.8644

0.65

0.0011

0.85

0.1556

Carnitine
CarnitineRelated
Metabolites

Palmitoylcarnitine
Stearoylcarnitine
Oleoylcarnitine

1.01 ±
0.164
0.906 ±
0.168
1.09 ±
0.122
0.997 ±
0.188

0.860 ±
0.159
0.629 ±
0.301
0.688 ±
0.333
0.640 ±
0.334

1.17
1.44
1.58
1.56

0.04
56
0.01
51
0.00
31
0.00
61

0.860 ±
0.159
0.629 ±
0.301
0.688 ±
0.333
0.640 ±
0.334
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1.06 ±
0.143
1.14 ±
0.266
1.18 ±
0.309
1.22 ±
0.364

1.23

0.0149

1.81

0.0013

1.71

0.002

1.91

0.0009

0.925 ±
0.086
1.05 ±
0.213
1.06 ±
0.288
1.13 ±
0.292

1.06 ±
0.143
1.14 ±
0.266
1.18 ±
0.309
1.22 ±
0.364

0.87

0.1321

0.92

0.717

0.9

0.5958

0.93

0.7329

Table 5-2. Distinct postprandial pattern in brain metabolism changes
between the CR and AL mice. Column 1 shows the comparison between the
CR and AL at 2-hr. Column 2 shows the comparison between AL mice at the 6hr vs. 2-hr time point. Colum 3 shows comparison between the CR and AL at 6hr. Representative data are shown as fold change between groups. The colorcoded boxes indicate the change of direction of the metabolites between groups.
Data are Mean ± SD. Red and green shaded cells indicate p ≤ 0.05 (red specifies
that the mean values are significantly higher for that comparison; green values
significantly lower). Metabolite specific P-values are listed in significance column.

Table 6-3. Differences of glycolysis- and pentose phosphate-related
metabolites in the young mice.

Fold
Chang
e

CR
Biochemical

2Hr
Fructose-6-Phosphate

0.928 ±
0.224

Glucose

0.987 ±
0.213

Glucose-6-Phosphate

0.965 ±
0.126

Lactate

0.966 ±
0.074

Alanine

0.960 ±
0.122

Isobar: Ribulose-5Phosphate, Xyulose- 5phosphate

1.14 ±
0.192

Arabitol

0.978 ±
0.184

6Hr
0.993
±
0.209
0.867
±
0.311
0.994
±
0.222
0.904
±
0.124
0.913
±
0.127
0.877
±
0.158
0.893
±
0.184

6Hr

Significan
ce

P-value

2Hr

1.07

0.5966

0.867 ±
0.291

0.88

0.3903

0.998 ±
0.303

1.03

0.9451

0.860 ±
0.310

0.94

0.3525

0.964 ±
0.215

0.95

0.4477

0.882 ±
0.143

0.77

0.0577

0.927 ±
0.425

0.91

0.3465

0.937 ±
0.206

2Hr
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Fold
Change

AL

6Hr
1.16
±
0.232
1.50
±
0.785
1.29
±
0.279
1.14
±
0.111
1.06
±
0.084
1.20
±
0.344
1.10
±
0.165

6Hr
2Hr

Significanc
e

P-value

1.34

0.0189

1.5

0.138

1.5

0.0051

1.18

0.0261

1.2

0.0097

1.29

0.03

1.17

0.121

Table 6-3. Differences of glycolysis- and pentose phosphate-related
metabolites in the young mice. Comparison between CR and AL groups at the
6-hr time point. Representative data are shown as fold change between groups.
The color-coded boxes indicated the change of direction of the metabolites
between the 2 hour and 6 hour time points within groups. Data are Mean ± SD.
Red shaded cells indicate p ≤ 0.05 and specify that the mean values are
significantly higher for that comparison. Metabolite specific P-values are listed in
significance column.

181

APPENDICES

APPENDIX 1: SUPPLEMENTARY DATA FROM CHAPTER 3
A. Circadian Rhythm Analysis

Actigraphic analysis was performed in light boxes built by
Phenome Technologies that allowed for control of light conditions independent of
animal room conditions. The light boxes were set for lights on at 7am and lights
off at 7pm for a 12:12 L:D cycle. Locomotor activity was continuously measured
by monitors placed on top of the food rack. Locomotor activity counts reflect the
frequency of movement of the animal across a grid. Each count reflects one
movement of the animal [254]. Animals were placed in light boxes one week
prior to injury to establish a baseline, 24 hours after injury for one week to
analyze acute locomotor activity and 6 weeks post-surgery to analyze sub-acute
locomotor activity. Daily rhythms of locomotor activity were analyzed using
cosinor analysis. Briefly, a cosine wave with a known period (24 hr) was fitted to
the data by the least squares method to estimate the pattern of the smooth
rhythm. The equation is as follows xi = M+Acos (θi+φ), where M is mesor, A is
amplitude, φ is acrophase and θi is trigonometric angles corresponding to
sampling time [255, 256]. Percent activity was found for the light and dark
periods and compared to each other to determine if movement is higher in the
dark or light period. To correlate with other measures, movements per 24 hours
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were averaged per group for the light and dark phase in order to have a singular
value to use in analysis.
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Supplementary figure 3-1. 24-hour activity circadian rhythm analysis.
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Supplementary figure 3-1. 24-hour activity circadian rhythm analysis. (A)
24-hour activity counts in all groups at all timepoints did not show any
differences. (B) 24-hour total counts of activity in sham before injury and 3 days
after injury. (C) 24-hour total counts of activity in CHI before injury and 3 days
after injury. (D) 24-hour total counts of activity in sham before injury and 6 weeks
after injury. Sham injured mice showed a significant decrease in activity 6 weeks
after injury compared to baseline. (E) 24-hour total counts of activity in CHI
before injury and 6 weeks after injury. *p < 0.05. Data are mean  SD.
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Supplementary Figure 3-2. Circadian rhythm cosinor analysis.
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Supplementary Figure 3-2. Circadian rhythm cosinor analysis. Cosinor
analysis showed no significant differences at any timepoint within Sham and CHI
or between injuries in (A) Amplitude, (B) MESOR and (C) Phase. (D) Summary
figure of circadian rhythm. Data are mean  SD.
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APPENDIX 2: SUPPLEMENTARY DATA FROM CHAPTER 4
B. Active avoidance behavioral paradigm

Active avoidance is used to evaluate fear-motivated associate
learning and memory. It has been found that a single mTBI (CHI) in mice can
cause persistent deficits in cognitive function [257]. Previous studies in rats fed
inulin showed improvement in cognitive performance [258] and humans fed
inulin showed greater accuracy in memory recognition and recall tests [259]. We
will use the active avoidance behavioral assay to assess if inulin is protective of
the cognitive deficits seen after CHI. Active avoidance assay was performed
using the methods described in [257]. Briefly, the mouse will be placed in a dark
box (Gemini shuttle box) with the guillotine door open so it can explore both
sides of the chamber for five minutes. Then a cue light will be turned on for ten
seconds and the mouse can choose to step into the safe side of the chamber (no
shock will be delivered) or stay on the dark side of the chamber and receive a
foot shock (2 second duration, 0.2 mA). The mouse will be exposed to 45
trials/day for five days.
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Supplemental Figure 4-1. Active Avoidance analysis.

189

Supplemental Figure 4-1. Active avoidance. At 2.5 months post injury, no
differences were seen in (A) Percent avoided, (B) Average latency and (C) sum
of crossings between groups.
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